name	nt_name	aa_name	multi_aa_name	multiaa_mutation_split_names	start	vcf_gene	chrom_region	mutation_type	dp	obs_sample_size	variant_pop_size	ps_filter	ps_exc	mat_pep_id	mat_pep_desc	mat_pep_acc	ro	ao_by_var_seq	ao	variant_seq	reference_seq	function_category	citation	citation_url	comb_mutation	function_description	heterozygosity	viral_lineages	clade_defining_status	status	voi_designation_date	voc_designation_date	vum_designation_date
5305	g.CACT15909_15912TACC	p.5305			16173	ORF1ab	ORF1b		41263	41348	41422			RNA-dependent RNA polymerase	nsp12, NiRAN and RdRp, produced by pp1ab only		12	TACC=1037	1037	TACC	CACT						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
A103S	g.G307T	p.A103S			25699	ORF3a	ORF3a	MISSENSE	41331	41348	41422						40894	T=436	436	T	G						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
A1222T	g.G3664A	p.A1222T			25226	S	S	MISSENSE	41321	41348	41422						40056	A=1265	1265	A	G						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
A1397A	g.C4191T	p.A1397A			4456	ORF1ab	ORF1a	SILENT	41301	41348	41422			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		41081	T=220	220	T	C						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
A1708D	g.C5123A	p.A1708D			5388	ORF1ab	ORF1a	MISSENSE	41256	41422	41422			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		0	A=41256	41256	A	C						False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=True, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
A211V	g.C632T	p.A211V			28905	N	N	MISSENSE	9	9	41422						1	T=8	8	T	C						False	Q.3	Q.3=True	de_escalated		18-Dec-2020	
A2320V	g.C6959T	p.A2320V			7224	ORF1ab	ORF1a	MISSENSE	64	64	41422			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		61	T=3	3	T	C						False	Q.4	Q.4=False	de_escalated		18-Dec-2020	
A239A	g.T717G	p.A239A			982	ORF1ab	ORF1a	SILENT	41309	41348	41422			nsp2	produced by both pp1a and pp1ab		41019	G=288	288	G	T						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
A2994V	g.C8981T	p.A2994V			9246	ORF1ab	ORF1a	MISSENSE	41256	41348	41422			nsp4	nsp4B_TM, contains transmembrane domain 2 (TM2), produced by both pp1a and pp1ab		40959	T=297	297	T	C						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
A3179A	g.G9537T	p.A3179A			9802	ORF1ab	ORF1a	SILENT	41315	41348	41422			nsp4	nsp4B_TM, contains transmembrane domain 2 (TM2), produced by both pp1a and pp1ab		40047	T=1268	1268	T	G						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
A336V	g.C1007T	p.A336V			29280	N	N	MISSENSE	41247	41348	41422						40232	T=1015	1015	T	C						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
A3523V	g.C10568T	p.A3523V			10833	ORF1ab	ORF1a	MISSENSE	41024	41348	41422			3C-like proteinase	nsp5A_3CLpro and nsp5B_3CLpro, main proteinase (Mpro), mediates cleavages downstream of nsp4. 3D structure of the SARSr-CoV homolog has been determined (Yang et al., 2003), produced by both pp1a and pp1ab		40801	T=223	223	T	C						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
A3730A	g.C11190T	p.A3730A			11455	ORF1ab	ORF1a	SILENT	41305	41348	41422			nsp6	nsp6_TM, putative transmembrane domain, produced by both pp1a and pp1ab		40571	T=734	734	T	C						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
A4577A	g.T13731G	p.A4577A			13995	ORF1ab	ORF1b	SILENT	41347	41348	41422			RNA-dependent RNA polymerase	nsp12, NiRAN and RdRp, produced by pp1ab only		40112	G=1235	1235	G	T						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
A475V	g.C1424T	p.A475V			22986	S	S	MISSENSE	41110	41348	41422						40147	T=963	963	T	C	antibody epitope effects	Gaebler et al. (2021)	https://www.biorxiv.org/content/10.1101/2020.11.03.367391v2		Ablates binding by class 3 mAbs such as C135 that do not directly interfere with ACE2 binding,  but clonal somatic mutations of memory B cells at 6.2 months (evolving humoral immune response)  show pronounced increase in binding to the variant. 	False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
A475V	g.C1424T	p.A475V			22986	S	S	MISSENSE	41110	41348	41422						40147	T=963	963	T	C	antibody epitope effects	Li et al. (2020)	https://www.sciencedirect.com/science/article/abs/pii/S0092867420308771		Resistent to some neutralizing antibodies: mAbs 157, 247, CB6, P2C-1F11, B38, and CA1	False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
A475V	g.C1424T	p.A475V			22986	S	S	MISSENSE	41110	41348	41422						40147	T=963	963	T	C	antibody epitope effects	Wang et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2		Resistent to some class 1 (Spike 'up' conformation) antibodies tested.	False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
A475V	g.C1424T	p.A475V			22986	S	S	MISSENSE	41110	41348	41422						40147	T=963	963	T	C	convalescent plasma escape	Li et al. (2020)	https://www.sciencedirect.com/science/article/abs/pii/S0092867420308771		Resistant to a pool of 10 convalescent sera (but less than 4x, a typical threshold for definition of escape)	False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
A475V	g.C1424T	p.A475V			22986	S	S	MISSENSE	41110	41348	41422						40147	T=963	963	T	C	monoclonal antibody serial passage escape	Barnes et al. (2020)	https://www.nature.com/articles/s41586-020-2852-1_reference.pdf?origin		The engineered mutation cause 10-fold or more increase in the disassociation constant with C102, C105 and C144 monoclonal antibodies vs. wild type Spike protein RBD domain AAs.	False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
A475V	g.C1424T	p.A475V			22986	S	S	MISSENSE	41110	41348	41422						40147	T=963	963	T	C	monoclonal antibody serial passage escape	Starr et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1		Escape mutation against monoclonal antibody LY-CoV016, minimal ACE2 binding affinity loss	False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
A475V	g.C1424T	p.A475V			22986	S	S	MISSENSE	41110	41348	41422						40147	T=963	963	T	C	pharmaceutical effectiveness	Engelhart et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1		COR-101 lost ~50x binding against this isolated mutation. Estesevimab lost ~8x binding against this isolated mutation. Sotrovimab lost ~30x binding against this isolated mutation. Tixagevimab lost ~15x binding against this isolated mutation. m396 lost ~8x binding against this isolated mutation.	False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
A516V	g.C1547T	p.A516V			1812	ORF1ab	ORF1a	MISSENSE	41319	41348	41422			nsp2	produced by both pp1a and pp1ab		41090	T=229	229	T	C						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
A5328V	g.C15983T	p.A5328V			16247	ORF1ab	ORF1b	MISSENSE	1	1	41422			helicase	nsp13_ZBD, nsp13_TB, and nsp_HEL1core, zinc-binding domain (ZD), NTPase/helicase domain (HEL), RNA 5'-triphosphatase, produced by pp1ab only		0	T=1	1	T	C						False	Q.1	Q.1=True	de_escalated		18-Dec-2020	
A570D	g.C1709A	p.A570D			23271	S	S	MISSENSE	41366	41422	41422						2	A=41362	41362	A	C	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	"Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.18x increase in binding (KD) relative to D614G, mostly due to decreased in ""off-rate"" a.k.a. dissociation rate (Kdis)."	False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=True, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
A570D	g.C1709A	p.A570D			23271	S	S	MISSENSE	41366	41422	41422						2	A=41362	41362	A	C	antibody epitope effects	Haynes et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.01.06.20248960v1		Wildtype elicits immune response, COVID-19 cohort epitope score > 99th percentile of the 497 pre-pandemic controls, mutant raises PIWAS epitope score from 3.6% to 6.2% (improved immune recognition) Together with other B1.1.7 lineage mutational changes (Spike: Y144del,N501Y, P681H, Nucleoprotein: D3L, S235F) resulted in only 2 of 579 individuals (0.3% of the population) having a dramatic reduction in PIWAS antigen scores, which reflects the peak epitope signal along the entire antigen.	False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=True, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
A570D	g.C1709A	p.A570D			23271	S	S	MISSENSE	41366	41422	41422						2	A=41362	41362	A	C	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	1.29x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=True, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
A570D	g.C1709A	p.A570D			23271	S	S	MISSENSE	41366	41422	41422						2	A=41362	41362	A	C	reinfection	Novazzi et al. (2021)	https://doi.org/10.1002/jmv.27066	'N501Y'	Partial sequencing of S gene reveals two cases of probable early 2021 B.1.1.7 lineage reinfection from non-B.1.1.7 original cases in Lombardy, with 45 to 90 days between infections (less than the typical 90 day guideline for this call). Patients were 56 and 58yo, immunocompenent, with one a former smoker with obesity and dyslipidemia. One case required intubation during first infection,  but presented with mild symptoms upon reinfection. The other case convalesced at home during the first episode, but required CPAP support  in the subacute clinical unit upon reinfection.	False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=True, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
A570D	g.C1709A	p.A570D			23271	S	S	MISSENSE	41366	41422	41422						2	A=41362	41362	A	C	trafficking	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1		Lentiviral pseudotyped with this individual mutation from B.1.1.7 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing statistically significant increased infection rate amongst the cells. 	False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=True, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
A570D	g.C1709A	p.A570D			23271	S	S	MISSENSE	41366	41422	41422						2	A=41362	41362	A	C	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	No significant change in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.04x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=True, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
A570D	g.C1709A	p.A570D			23271	S	S	MISSENSE	41366	41422	41422						2	A=41362	41362	A	C	virion structure	Spratt et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1		Estimated that there is very little free energy change (ddG. -0.02 kcal/mol) for this variant (i.e. approx. same stability as wild type) 	False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=True, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
A570D	g.C1709A	p.A570D			23271	S	S	MISSENSE	41366	41422	41422						2	A=41362	41362	A	C	virion structure	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1		The Ratio of S2 (processed Spike) to full length Spike is higher for this mutation,  due to a drop in the full length Spike measured, suggesting that this mutation compensates for decreased Spike production by improved proteolytic processing.	False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=True, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
A6044S	g.G18130T	p.A6044S			18394	ORF1ab	ORF1b	MISSENSE	64	64	41422			3'-to-5' exonuclease	nsp14A2_ExoN and nsp14B_NMT, produced by pp1ab only		63	T=1	1	T	G						False	Q.4	Q.4=False	de_escalated		18-Dec-2020	
A656V	g.C1967T	p.A656V			2232	ORF1ab	ORF1a	MISSENSE	1	1	41422			nsp2	produced by both pp1a and pp1ab		0	T=1	1	T	C						False	Q.1	Q.1=True	de_escalated		18-Dec-2020	
A6990A	g.C20970T	p.A6990A			21234	ORF1ab	ORF1b	SILENT	40209	41349	41422			2'-O-ribose methyltransferase	nsp16_OMT, 2'-o-MT, produced by pp1ab only		34149	T=6060	6060	T	C						False	Q.1, B.1.1.7	B.1.1.7=False, Q.1=True	de_escalated		18-Dec-2020	
A892V	g.C2675T	p.A892V			24237	S	S	MISSENSE	40908	41348	41422						40661	T=247	247	T	C						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
A98V	g.C293T	p.A98V			25685	ORF3a	ORF3a	MISSENSE	64	64	41422						60	T=4	4	T	C						False	Q.4	Q.4=False	de_escalated		18-Dec-2020	
C19C	g.C57T	p.C19C			29614	ORF10	ORF10	SILENT	41191	41348	41422						39845	T=1346	1346	T	C						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
C4163C	g.C12489T	p.C4163C			12754	ORF1ab	ORF1a	SILENT	64	64	41422			nsp9	ssRNA-binding protein, produced by both pp1a and pp1ab		63	T=1	1	T	C						False	Q.4	Q.4=False	de_escalated		18-Dec-2020	
C5205C	g.C15615T	p.C5205C			15879	ORF1ab	ORF1b	SILENT	41288	41348	41422			RNA-dependent RNA polymerase	nsp12, NiRAN and RdRp, produced by pp1ab only		41023	T=265	265	T	C						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
C61F	g.G182T	p.C61F			28075	ORF8	ORF8	MISSENSE	40284	41348	41422						39534	T=749	749	T	G						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
D1044D	g.C3132T	p.D1044D			3397	ORF1ab	ORF1a	SILENT	41264	41348	41422			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		40058	T=1206	1206	T	C						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
D1118H	g.G3352C	p.D1118H			24914	S	S	MISSENSE	41416	41422	41422						2	C=40089	40089	C	G	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	"Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.23x increase in binding (KD) relative to D614G, mostly due to decreased in ""off-rate"" a.k.a. dissociation rate (Kdis)."	False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=True, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
D1118H	g.G3352C	p.D1118H			24914	S	S	MISSENSE	41416	41422	41422						2	C=40089	40089	C	G	T cell evasion	Reynolds et al. (2021)	https://science.sciencemag.org/content/early/2021/04/29/science.abh1282		Mutation is predicted to lose the T cell epitope for people carrying DRB1*0301 and DRB1*0401,  but not for example in those who are DRB1*0701 or DRB1*1501 who would be predicted to show an enhanced response. This is also observed in a study of 26 each post-infection and post first dose HCWs.	False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=True, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
D1118H	g.G3352C	p.D1118H			24914	S	S	MISSENSE	41416	41422	41422						2	C=40089	40089	C	G	antibody epitope effects	Haynes et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.01.06.20248960v1		Not in a major wildtype epitope, mutant has no significant effect on PIWAS epitope score Found in B.1.1.7 lineage, but assumed to not pay a major role in antigenicity.	False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=True, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
D1118H	g.G3352C	p.D1118H			24914	S	S	MISSENSE	41416	41422	41422						2	C=40089	40089	C	G	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	1.96x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=True, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
D1118H	g.G3352C	p.D1118H			24914	S	S	MISSENSE	41416	41422	41422						2	C=40089	40089	C	G	trafficking	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1		Lentiviral pseudotyped with this individual mutation from B.1.1.7 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing mild decrease in infection rate amongst the cells, hence this individual variant  is unlikely to contribute to cell entry fitness. 	False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=True, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
D1118H	g.G3352C	p.D1118H			24914	S	S	MISSENSE	41416	41422	41422						2	C=40089	40089	C	G	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	1.09x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.08x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=True, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
D1118Y	g.G3352T	p.D1118Y			24914	S	S	MISSENSE	41342	41348	41422						2	T=1325	1325	T	G						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
D1184D	g.C3552T	p.D1184D			3817	ORF1ab	ORF1a	SILENT	41273	41348	41422			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		41013	T=255	255	T	C						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
D1259D	g.C3777T	p.D1259D			25339	S	S	SILENT	64	64	41422						63	T=1	1	T	C						False	Q.4	Q.4=False	de_escalated		18-Dec-2020	
D1273D	g.C3819T	p.D1273D			4084	ORF1ab	ORF1a	SILENT	41260	41348	41422			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		40937	T=323	323	T	C						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
D178H	g.G532C	p.D178H			22094	S	S	MISSENSE	9	9	41422						1	C=8	8	C	G						False	Q.3	Q.3=True	de_escalated		18-Dec-2020	
D1897D	g.C5691T	p.D1897D			5956	ORF1ab	ORF1a	SILENT	64	64	41422			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		63	T=1	1	T	C						False	Q.4	Q.4=False	de_escalated		18-Dec-2020	
D2101D	g.C6303T	p.D2101D			6568	ORF1ab	ORF1a	SILENT	9	9	41422			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		1	T=8	8	T	C						False	Q.3	Q.3=True	de_escalated		18-Dec-2020	
D253Y	g.G757T	p.D253Y			22319	S	S	MISSENSE	41278	41348	41422						40772	T=506	506	T	G	antibody epitope effects	McCallum et al. (2021)	https://doi.org/10.1101/2021.01.14.426475		"Massive reduction in S2L28 monoclonal antibody EC50 (i.e. ablated recognition), within antigenic supersite ""i"", but no effect on other mAbs within that supersite"	False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
D2573D	g.T7719C	p.D2573D			7984	ORF1ab	ORF1a	SILENT	41332	41348	41422			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		40603	C=729	729	C	T						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
D3196D	g.T9588C	p.D3196D			9853	ORF1ab	ORF1a	SILENT	41290	41348	41422			nsp4	nsp4B_TM, contains transmembrane domain 2 (TM2), produced by both pp1a and pp1ab		32660	C=8630	8630	C	T						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
D341D	g.C1023T	p.D341D			29296	N	N	SILENT	41245	41348	41422						40786	T=458	458	T	C						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
D3508D	g.C10524T	p.D3508D			10789	ORF1ab	ORF1a	SILENT	64	64	41422			3C-like proteinase	nsp5A_3CLpro and nsp5B_3CLpro, main proteinase (Mpro), mediates cleavages downstream of nsp4. 3D structure of the SARSr-CoV homolog has been determined (Yang et al., 2003), produced by both pp1a and pp1ab		63	T=1	1	T	C						False	Q.4	Q.4=False	de_escalated		18-Dec-2020	
D3L	g.GAT7_9CTA	p.D3L			28280	N	N		41165	41422	41422						2	CTA=41153	41153	CTA	GAT	subgenomic RNA expression	Parker et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.02.433156v1		A noncanonical subgenomic RNA which could represent ORF9b is significantly enriched (~16x) in B.1.1.7 SARS-CoV-2 infections,  potentially as a result of a triple nucleotide mutation leading to amino acid substitution D3L  in nucleocapsid in this lineage which increases complementarity with the genomic leader sequence. 	False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=True, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
D3L	g.GAT7_9CTA	p.D3L			28280	N	N		41165	41422	41422						2	CTA=41153	41153	CTA	GAT	variant linear antibody epitope effects	Haynes et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.01.06.20248960v1		At the epitope level, the D3L mutation reduces PIWAS signal in 1.5% of COVID patients (outliers reduce from 2.1% in wild type to 0.5% in mutant). In 3 of these patients (0.5% of the population), that alteration represents the strongest antigen signal and substantially reduces the PIWAS antigen score. In the B1.1.7 lineage this is largely counteracted by the S235F mutation, which increases epitope and antigen scores significantly in two individuals, for a net neutral effect at the population level.	False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=True, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
D4344D	g.C13032T	p.D4344D			13297	ORF1ab	ORF1a	SILENT	64	64	41422			nsp10	nsp10_CysHis, formerly known as growth-factor-like protein (GFL), produced by both pp1a and pp1ab		63	T=1	1	T	C						False	Q.4	Q.4=False	de_escalated		18-Dec-2020	
D4452D	g.C13356T	p.D4452D			13620	ORF1ab	ORF1b	SILENT	62	64	41422			RNA-dependent RNA polymerase	nsp12, NiRAN and RdRp, produced by pp1ab only		61	T=1	1	T	C						False	Q.4	Q.4=False	de_escalated		18-Dec-2020	
D4532D	g.C13596T	p.D4532D			13860	ORF1ab	ORF1b	SILENT	64	64	41422			RNA-dependent RNA polymerase	nsp12, NiRAN and RdRp, produced by pp1ab only		63	T=1	1	T	C						False	Q.4	Q.4=False	de_escalated		18-Dec-2020	
D4652D	g.C13956T	p.D4652D			14220	ORF1ab	ORF1b	SILENT	1	1	41422			RNA-dependent RNA polymerase	nsp12, NiRAN and RdRp, produced by pp1ab only		0	T=1	1	T	C						False	Q.1	Q.1=True	de_escalated		18-Dec-2020	
D48N	g.G142A	p.D48N			407	ORF1ab	ORF1a	MISSENSE	41330	41348	41422			leader protein	nsp1, produced by both pp1a and pp1ab		41022	A=308	308	A	G						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
D5152D	g.C15456T	p.D5152D			15720	ORF1ab	ORF1b	SILENT	41284	41348	41422			RNA-dependent RNA polymerase	nsp12, NiRAN and RdRp, produced by pp1ab only		39700	T=1584	1584	T	C						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
D5484D	g.C16452T	p.D5484D			16716	ORF1ab	ORF1b	SILENT	41311	41348	41422			helicase	nsp13_ZBD, nsp13_TB, and nsp_HEL1core, zinc-binding domain (ZD), NTPase/helicase domain (HEL), RNA 5'-triphosphatase, produced by pp1ab only		40568	T=485	485	T	C						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
D5484E	g.C16452G	p.D5484E			16716	ORF1ab	ORF1b	MISSENSE	41311	41348	41422			helicase	nsp13_ZBD, nsp13_TB, and nsp_HEL1core, zinc-binding domain (ZD), NTPase/helicase domain (HEL), RNA 5'-triphosphatase, produced by pp1ab only		40568	G=258	258	G	C						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	41371	41422	41422						1	G=41307, GTT=1	41307,1	G,GTT	A	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'A570D'	"Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.18x increase in binding (KD) relative to D614G, mostly due to decreased in ""off-rate"" a.k.a. dissociation rate (Kdis)."	False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=False, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	41371	41422	41422						1	G=41307, GTT=1	41307,1	G,GTT	A	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D1118H'	"Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.23x increase in binding (KD) relative to D614G, mostly due to decreased in ""off-rate"" a.k.a. dissociation rate (Kdis)."	False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=False, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	41299	41349	41422						1	G=41298	41298	G	A	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'L5F'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.1x decrease in binding (KD) relative to D614G.	False	Q.1, B.1.1.7	B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	41371	41422	41422						1	G=41307, GTT=1	41307,1	G,GTT	A	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'N501Y'	"Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 2.52x increase in binding (KD) relative to D614G, mostly due to decreased in ""off-rate"" a.k.a. dissociation rate (Kdis). Compare to full Spike variant complements for major lineages containing this variant subset: 5.43x (B.1.1.7 aka Alpha), 3.56x (B.1.351 aka Beta), 4.24x (P.1 aka Gamma)."	False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=False, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	41371	41422	41422						1	G=41307, GTT=1	41307,1	G,GTT	A	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'P681H'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.23x decrease in binding (KD) relative to D614G.	False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=False, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	41371	41422	41422						1	G=41307, GTT=1	41307,1	G,GTT	A	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'S982A'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.3x decrease in binding (KD) relative to D614G.	False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=False, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	41371	41422	41422						1	G=41307, GTT=1	41307,1	G,GTT	A	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'T716I'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.12x decrease in binding (KD) relative to D614G.	False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=False, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	41371	41422	41422						1	G=41307, GTT=1	41307,1	G,GTT	A	ACE2 receptor binding affinity	Li et al. (2020)	https://doi.org/10.1016/j.cell.2020.07.012		In four cell lines (including 293T-hACE2 cells), this mutation combination increases infectivity vs D614G alone	False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=False, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	41371	41422	41422						1	G=41307, GTT=1	41307,1	G,GTT	A	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'A570D'	1.29x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=False, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	41371	41422	41422						1	G=41307, GTT=1	41307,1	G,GTT	A	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D1118H'	1.96x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=False, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	41299	41349	41422						1	G=41298	41298	G	A	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'L5F'	No change in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	Q.1, B.1.1.7	B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	41371	41422	41422						1	G=41307, GTT=1	41307,1	G,GTT	A	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'N501Y'	1.65x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=False, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	41371	41422	41422						1	G=41307, GTT=1	41307,1	G,GTT	A	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'P681H'	1.26x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=False, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	41371	41422	41422						1	G=41307, GTT=1	41307,1	G,GTT	A	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'S982A'	1.06x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=False, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	41371	41422	41422						1	G=41307, GTT=1	41307,1	G,GTT	A	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'T716I'	1.58x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=False, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	41371	41422	41422						1	G=41307, GTT=1	41307,1	G,GTT	A	immunosuppression variant emergence	Landis et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.05.08.21256775v1		Studying 94 COVID-19 extended infection cases with genomics April 1 to October 17, 2020, one case developed 23 mutations in a 19 day period, including this combination in Spike.	False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=False, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	41371	41422	41422						1	G=41307, GTT=1	41307,1	G,GTT	A	syncytium formation	Kim et al. (2021)	https://dx.doi.org/10.3390%2Fv13040633		Slight increase in Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus.	False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=False, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	41371	41422	41422						1	G=41307, GTT=1	41307,1	G,GTT	A	syncytium formation	Kim et al. (2021)	https://dx.doi.org/10.3390%2Fv13040633	'N501Y'	Slight increase in Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus relative to wild type, no change relative to D614G.	False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=False, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	41371	41422	41422						1	G=41307, GTT=1	41307,1	G,GTT	A	tissue specific neutralization	Planas et al. (2021)	https://www.nature.com/articles/s41591-021-01318-5		The nasal mucosa of Pfizer vaccinees with time course collection was evaluated against VSV pseudotypes: results (only one nasal  swab from different previously infected vacinee neutralizing at weeks 3 and 6 against B.1.1.7 and D614G) suggest that vaccinees probably  do not elicit an early humoral response detectable at mucosal surfaces even though sera neutralization was observed. They strengthen the hypothesis that some vaccines may not protect against  viral acquisition and infection of the oral–nasal region, but may prevent severe disease associated with viral dissemination in the lower respiratory tract. 	False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=False, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	41371	41422	41422						1	G=41307, GTT=1	41307,1	G,GTT	A	trafficking	Barrett et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.24.428007v1		Circulating variant shown in vitro to not have major defects or enhancement of cell surface protein trafficking (i.e. Spike cleavage or fusion required for cell entry)	False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=False, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	41371	41422	41422						1	G=41307, GTT=1	41307,1	G,GTT	A	trafficking	Daniloski et al. (2021)	https://doi.org/10.7554/elife.65365		The increased transduction with Spike D614G ranged from 1.3- to 2.4-fold in Caco-2 and Calu-3 cells expressing  endogenous ACE2 and from 1.5- to 7.7-fold in A549ACE2 and Huh7.5ACE2 overexpressing ACE2.  Although there is minimal difference in ACE2 receptor binding between the D614 and G614 Spike variants,  the G614 variant is more resistant to proteolytic cleavage, suggesting a possible mechanism for the increased transduction.	False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=False, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	41371	41422	41422						1	G=41307, GTT=1	41307,1	G,GTT	A	trafficking	Kim et al. (2021)	https://dx.doi.org/10.3390%2Fv13040633		No change in infectivity (24h) relative to D614G alone in Caco-2 cells, Vero or Calu-3.	False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=False, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	41371	41422	41422						1	G=41307, GTT=1	41307,1	G,GTT	A	trafficking	Kim et al. (2021)	https://dx.doi.org/10.3390%2Fv13040633		~4x more efficient S2 domain cleavage compared to wild type in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3).	False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=False, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	41371	41422	41422						1	G=41307, GTT=1	41307,1	G,GTT	A	trafficking	Kim et al. (2021)	https://dx.doi.org/10.3390%2Fv13040633	'N501Y'	More efficient infectivity (24h) compared to wild type, in Caco-2 cells ~9x, Vero ~8x, and Calu-3 ~8x. Compare to wild type at ~5x across cell types.	False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=False, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	41371	41422	41422						1	G=41307, GTT=1	41307,1	G,GTT	A	trafficking	Kim et al. (2021)	https://dx.doi.org/10.3390%2Fv13040633	'N501Y'	~4x more efficient S2 domain cleavage compared to wild type, no change relative to D614G alone in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3).	False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=False, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	82669	82844	41422						2	G=82605	82605	G	A	trafficking	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'N501Y'	9x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.	False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=False, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	41371	41422	41422						1	G=41307, GTT=1	41307,1	G,GTT	A	trafficking	Ozono et al. (2020)	https://www.nature.com/articles/s41467-021-21118-2		Among S variants tested, the D614G mutant shows the highest cell entry (~3.5x wild type), as supported by  structural and binding analyses. 	False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=False, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	63	64	41422						0	GTT=1	1	GTT	ATG	trafficking	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.05.14.444076v1	'P681R'	Quantification of the band intensities showed that the P681R mutation, which lies near the proteolytic processing site,  caused a small increase in proteolytic processing as measured by a 2-fold decrease in the ratio of S/S2.	False	Q.4	Q.4=False	de_escalated		18-Dec-2020	
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	41371	41422	41422						1	G=41307, GTT=1	41307,1	G,GTT	A	trafficking	Zhang et l. (2020)	https://www.nature.com/articles/s41467-020-19808-4		We report here pseudoviruses carrying SG614 enter ACE2-expressing cells more efficiently than wild type (~9-fold).  This increased entry correlates with less S1-domain shedding and higher S-protein incorporation into the virion.  D614G does not alter S-protein binding to ACE2 or neutralization sensitivity of pseudoviruses. Thus, D614G may  increase infectivity by assembling more functional S protein into the virion.	False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=False, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	41371	41422	41422						1	G=41307, GTT=1	41307,1	G,GTT	A	vaccine neutralization efficacy	Garcia-Beltran et al. (2021)	https://doi.org/10.1016/j.cell.2021.03.013		Pseudotyped D614G virus has reduced neutralization activity vs wild type: 1.2x (37 sera Pfizer median 9  days post 2nd dose, 37 sera Moderna median 18 days post 2nd dose). This was NOT significant by ANOVA.	False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=False, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	41371	41422	41422						1	G=41307, GTT=1	41307,1	G,GTT	A	vaccine neutralization efficacy	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008		Using a lentivirus virus pseudotyped with D614G Spike, sera from vaccinated individuals who received the second dose (9–11 days post-second dose of Pfizer) exhibited a robust  neutralizing potential, with a mean NT50 value of 99,000. This was an average of a 2-fold increase, relative to sera drawn from the  individuals who received one dose of vaccination—mean NT50 dilution of 51,300. Importantly, a 6-fold increase in mean NT50 dilution was  obtained when sera from the first vaccination dose was compared to convalescent sera from cohort with severe disease (NT50 51,000 vs 8,700)  21 to 63 days post-onset. 	False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=False, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	41371	41422	41422						1	G=41307, GTT=1	41307,1	G,GTT	A	vaccine neutralization efficacy	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'N501Y'	This variant showed no change in Pfizer sera (one or two dose) neutralization efficiency vs D614G (using lentivirus pseudotype).	False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=False, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	41371	41422	41422						1	G=41307, GTT=1	41307,1	G,GTT	A	vaccine neutralization efficacy	Zuckerman et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.03.25.21253908v1	'P681H'	No significant change in virus neutralzation by 18 Pfizer two dose vaccinee sera compared to B.1.1.7. [results without including the used mutation A27S likely generalizable, as this is not a lineage defining mutation]	False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=False, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	41371	41422	41422						1	G=41307, GTT=1	41307,1	G,GTT	A	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'A570D'	No significant change in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.04x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=False, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	41371	41422	41422						1	G=41307, GTT=1	41307,1	G,GTT	A	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D1118H'	1.09x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.08x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=False, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	41299	41349	41422						1	G=41298	41298	G	A	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'L5F'	1.23x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.1x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	Q.1, B.1.1.7	B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	41371	41422	41422						1	G=41307, GTT=1	41307,1	G,GTT	A	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'N501Y'	1.17x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.09x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=False, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	41371	41422	41422						1	G=41307, GTT=1	41307,1	G,GTT	A	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'P681H'	1.14x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.11x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=False, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	41371	41422	41422						1	G=41307, GTT=1	41307,1	G,GTT	A	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'S982A'	2x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.12x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=False, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	41371	41422	41422						1	G=41307, GTT=1	41307,1	G,GTT	A	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'T716I'	1.02x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.47x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=False, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	41371	41422	41422						1	G=41307, GTT=1	41307,1	G,GTT	A	viral load	Plante et al. (2020)	https://www.nature.com/articles/s41586-020-2895-3		Hamsters infected with SARS-CoV-2 expressing spike(D614G) (G614 virus) produced higher infectious titres in nasal washes and the trachea, but not in the lungs,  supporting clinical evidence showing that the mutation enhances viral loads in the upper respiratory tract of COVID-19 patients and may increase transmission.	False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=False, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	41371	41422	41422						1	G=41307, GTT=1	41307,1	G,GTT	A	virion structure	Spratt et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1		Estimated free energy change (ddG) for this variant is 2.5 kcal/mol (i.e. stabilizing relative to wild type) 	False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=False, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	41371	41422	41422						1	G=41307, GTT=1	41307,1	G,GTT	A	virion structure	Weissman et al. (2020)	https://www.medrxiv.org/content/10.1101/2020.07.22.20159905v2		"Negative stain EM shows increased proportion of ""one-up"" trimer conformation of Spike proteins on the surface of virions, where the up  conformation is presumed to be more likely to bind ACE2."	False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=False, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	41371	41422	41422						1	G=41307, GTT=1	41307,1	G,GTT	A	virion structure	Yurkovetskiy et al. (2020)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7492024/		"CryoEM shows increased proportion of ""one-up"" trimer conformation of Spike proteins on the surface of virions, where the up  conformation is presumed to be more likely to bind ACE2."	False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=False, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	41371	41422	41422						1	G=41307, GTT=1	41307,1	G,GTT	A	virion structure	Zhang et al. (2020)	https://www.nature.com/articles/s41467-020-19808-4		Based on pseudotyped virus experiments, D614G may increase infectivity by assembling more functional S protein into the virion.	False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=False, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
D61L	g.GAT181_183CTC	p.D61L			27382	ORF6	ORF6		41257	41348	41422						40778	CTC=254	254	CTC	GAT						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
D6249D	g.C18747T	p.D6249D			19011	ORF1ab	ORF1b	SILENT	41409	41412	41422			3'-to-5' exonuclease	nsp14A2_ExoN and nsp14B_NMT, produced by pp1ab only		40348	T=1061	1061	T	C						False	B.1.1.7, Q.4	Q.4=False, B.1.1.7=False	de_escalated		18-Dec-2020	
D6900N	g.G20698A	p.D6900N			20962	ORF1ab	ORF1b	MISSENSE	9	9	41422			2'-O-ribose methyltransferase	nsp16_OMT, 2'-o-MT, produced by pp1ab only		0	A=9	9	A	G						False	Q.3	Q.3=True	de_escalated		18-Dec-2020	
D795D	g.C2385T	p.D795D			2650	ORF1ab	ORF1a	SILENT	64	64	41422			nsp2	produced by both pp1a and pp1ab		60	T=4	4	T	C						False	Q.4	Q.4=False	de_escalated		18-Dec-2020	
DV614GF	g.ATG1841_1843GTT	p.DV614GF			23403	S	S		63	64	41422						0	GTG=62	62	GTG	ATG						False	Q.4	Q.4=True	de_escalated		18-Dec-2020	
E102E	g.A306G	p.E102E			25698	ORF3a	ORF3a	SILENT	41334	41348	41422						40153	G=1181	1181	G	A						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
E106X	g.G316T	p.E106X			28209	ORF8	ORF8	NONSENSE	40324	41348	41422						39104	T=1218	1218	T	G						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
E22D	g.G66T	p.E22D			27459	ORF7a	ORF7a	MISSENSE	41262	41348	41422						41025	T=231	231	T	G						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
E266X	g.G796T	p.E266X			26188	ORF3a	ORF3a	NONSENSE	41310	41348	41422						40722	T=588	588	T	G						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
E3310E	g.A9930G	p.E3310E			10195	ORF1ab	ORF1a	SILENT	41327	41348	41422			3C-like proteinase	nsp5A_3CLpro and nsp5B_3CLpro, main proteinase (Mpro), mediates cleavages downstream of nsp4. 3D structure of the SARSr-CoV homolog has been determined (Yang et al., 2003), produced by both pp1a and pp1ab		40570	G=752	752	G	A						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
E780Q	g.G2338C	p.E780Q			23900	S	S	MISSENSE	64	64	41422						53	C=11	11	C	G						False	Q.4	Q.4=False	de_escalated		18-Dec-2020	
F100F	g.C300T	p.F100F			26822	M	M	SILENT	41345	41348	41422						40989	T=355	355	T	C						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
F16S	g.T47C	p.F16S			27940	ORF8	ORF8	MISSENSE	40288	41348	41422						39825	C=463	463	C	T						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
F1907F	g.C5721T	p.F1907F			5986	ORF1ab	ORF1a	SILENT	41183	41422	41422			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		0	T=41183	41183	T	C						False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=True, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
F1925F	g.C5775T	p.F1925F			6040	ORF1ab	ORF1a	SILENT	41180	41348	41422			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		40885	T=295	295	T	C						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
F2780L	g.T8338C	p.F2780L			8603	ORF1ab	ORF1a	MISSENSE	41264	41348	41422			nsp4	nsp4B_TM, contains transmembrane domain 2 (TM2), produced by both pp1a and pp1ab		39329	C=1935	1935	C	T						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
F28L	g.T82C	p.F28L			26604	M	M	MISSENSE	41315	41348	41422						38550	C=2765	2765	C	T						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
F31L	g.T91C	p.F31L			356	ORF1ab	ORF1a	MISSENSE	41322	41348	41422			leader protein	nsp1, produced by both pp1a and pp1ab		41086	C=236	236	C	T						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
F3329F	g.C9987T	p.F3329F			10252	ORF1ab	ORF1a	SILENT	41327	41348	41422			3C-like proteinase	nsp5A_3CLpro and nsp5B_3CLpro, main proteinase (Mpro), mediates cleavages downstream of nsp4. 3D structure of the SARSr-CoV homolog has been determined (Yang et al., 2003), produced by both pp1a and pp1ab		41100	T=227	227	T	C						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
F346F	g.C1038T	p.F346F			29311	N	N	SILENT	64	64	41422						63	T=1	1	T	C						False	Q.4	Q.4=False	de_escalated		18-Dec-2020	
F3770F	g.C11310T	p.F3770F			11575	ORF1ab	ORF1a	SILENT	41313	41348	41422			nsp6	nsp6_TM, putative transmembrane domain, produced by both pp1a and pp1ab		33268	T=8045	8045	T	C						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
F53F	g.C159T	p.F53F			26681	M	M	SILENT	41316	41348	41422						41087	T=229	229	T	C						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
F543F	g.C1629T	p.F543F			23191	S	S	SILENT	41294	41349	41422						37843	T=3451	3451	T	C						False	Q.1, B.1.1.7	B.1.1.7=False, Q.1=True	de_escalated		18-Dec-2020	
F5823F	g.C17469T	p.F5823F			17733	ORF1ab	ORF1b	SILENT	41290	41348	41422			helicase	nsp13_ZBD, nsp13_TB, and nsp_HEL1core, zinc-binding domain (ZD), NTPase/helicase domain (HEL), RNA 5'-triphosphatase, produced by pp1ab only		40998	T=292	292	T	C						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
F6947F	g.T20841C	p.F6947F			21105	ORF1ab	ORF1b	SILENT	64	64	41422			2'-O-ribose methyltransferase	nsp16_OMT, 2'-o-MT, produced by pp1ab only		63	C=1	1	C	T						False	Q.4	Q.4=False	de_escalated		18-Dec-2020	
F6948F	g.C20844T	p.F6948F			21108	ORF1ab	ORF1b	SILENT	41102	41357	41422			2'-O-ribose methyltransferase	nsp16_OMT, 2'-o-MT, produced by pp1ab only		40561	T=541	541	T	C						False	B.1.1.7, Q.3	Q.3=False, B.1.1.7=False	de_escalated		18-Dec-2020	
F924F	g.C2772T	p.F924F			3037	ORF1ab	ORF1a	SILENT	41417	41422	41422			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		0	T=41417	41417	T	C						False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=True, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
G142_Y144delinsVV	g.GTGTTTA425_431TTGT	p.G142_Y144delinsVV			21987	S	S		39550	41348	41422						856	TTGTTTAC=228	228	TTGTTTAC	GTGTTTATTAC						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
G18V	g.G53T	p.G18V			25445	ORF3a	ORF3a	MISSENSE	41335	41348	41422						40986	T=349	349	T	G						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
G254R	g.G760A	p.G254R			26152	ORF3a	ORF3a	MISSENSE	64	64	41422						63	A=1	1	A	G						False	Q.4	Q.4=False	de_escalated		18-Dec-2020	
G2959C	g.G8875T	p.G2959C			9140	ORF1ab	ORF1a	MISSENSE	64	64	41422			nsp4	nsp4B_TM, contains transmembrane domain 2 (TM2), produced by both pp1a and pp1ab		63	T=1	1	T	G						False	Q.4	Q.4=False	de_escalated		18-Dec-2020	
G298S	g.G892A	p.G298S			1157	ORF1ab	ORF1a	MISSENSE	41344	41348	41422			nsp2	produced by both pp1a and pp1ab		41023	A=320	320	A	G						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
G38V	g.G113T	p.G38V			27506	ORF7a	ORF7a	MISSENSE	41234	41348	41422						40914	T=318	318	T	G						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
G3923R	g.G11767C	p.G3923R			12032	ORF1ab	ORF1a	MISSENSE	64	64	41422			nsp7	produced by both pp1a and pp1ab		61	C=3	3	C	G						False	Q.4	Q.4=False	de_escalated		18-Dec-2020	
G5231G	g.G15693A	p.G5231G			15957	ORF1ab	ORF1b	SILENT	41292	41348	41422			RNA-dependent RNA polymerase	nsp12, NiRAN and RdRp, produced by pp1ab only		40051	A=1239	1239	A	G						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
G6598S	g.G19792A	p.G6598S			20056	ORF1ab	ORF1b	MISSENSE	41199	41348	41422	mask	ambiguous,homoplasic,single_src	endoRNAse	nsp15-A1 and nsp15B-NendoU, produced by pp1ab only		40962	A=237	237	A	G						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
G6788G	g.C20364T	p.G6788G			20628	ORF1ab	ORF1b	SILENT	41289	41348	41422			endoRNAse	nsp15-A1 and nsp15B-NendoU, produced by pp1ab only		41076	T=213	213	T	C						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
H1108Y	g.C3322T	p.H1108Y			3587	ORF1ab	ORF1a	MISSENSE	41256	41348	41422			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		40068	T=1188	1188	T	C						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
H1545H	g.C4635T	p.H1545H			4900	ORF1ab	ORF1a	SILENT	41315	41348	41422			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		39848	T=1467	1467	T	C						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
H2659Y	g.C7975T	p.H2659Y			8240	ORF1ab	ORF1a	MISSENSE	64	64	41422			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		60	T=4	4	T	C						False	Q.4	Q.4=False	de_escalated		18-Dec-2020	
H42H	g.C126T	p.H42H			27881	ORF7b	ORF7b	SILENT	40286	41348	41422						40033	T=253	253	T	C						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
H5005H	g.C15015T	p.H5005H			15279	ORF1ab	ORF1b	SILENT	41375	41422	41422			RNA-dependent RNA polymerase	nsp12, NiRAN and RdRp, produced by pp1ab only		1	T=41374	41374	T	C						False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=True, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
H5788Y	g.C17362T	p.H5788Y			17626	ORF1ab	ORF1b	MISSENSE	41346	41348	41422			helicase	nsp13_ZBD, nsp13_TB, and nsp_HEL1core, zinc-binding domain (ZD), NTPase/helicase domain (HEL), RNA 5'-triphosphatase, produced by pp1ab only		40823	T=523	523	T	C						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
H69fs	g.204_208delACATG	p.H69fs			21763	S	S		40663	41348	41422			(S|GU280_gp02|1|1.00)			8	TAT=40150	40150	TAT	TATACATGT						False	B.1.1.7	B.1.1.7=True	de_escalated		18-Dec-2020	
H78Y	g.C232T	p.H78Y			25624	ORF3a	ORF3a	MISSENSE	41339	41348	41422						41110	T=229	229	T	C						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
I1215T	g.T3644C	p.I1215T			3909	ORF1ab	ORF1a	MISSENSE	64	64	41422			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		63	C=1	1	C	T						False	Q.4	Q.4=False	de_escalated		18-Dec-2020	
I20I	g.C60T	p.I20I			25452	ORF3a	ORF3a	SILENT	41336	41348	41422						40996	T=340	340	T	C						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
I2230T	g.T6689C	p.I2230T			6954	ORF1ab	ORF1a	MISSENSE	41349	41422	41422			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		9	C=41340	41340	C	T						False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=True, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
I2895I	g.C8685T	p.I2895I			8950	ORF1ab	ORF1a	SILENT	41344	41349	41422			nsp4	nsp4B_TM, contains transmembrane domain 2 (TM2), produced by both pp1a and pp1ab		37378	T=3966	3966	T	C						False	Q.1, B.1.1.7	B.1.1.7=False, Q.1=True	de_escalated		18-Dec-2020	
I5804I	g.C17412T	p.I5804I			17676	ORF1ab	ORF1b	SILENT	41344	41348	41422			helicase	nsp13_ZBD, nsp13_TB, and nsp_HEL1core, zinc-binding domain (ZD), NTPase/helicase domain (HEL), RNA 5'-triphosphatase, produced by pp1ab only		41032	T=312	312	T	C						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
I712V	g.A2134G	p.I712V			23696	S	S	MISSENSE	40860	41348	41422						40412	G=448	448	G	A						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
K1051R	g.A3152G	p.K1051R			3417	ORF1ab	ORF1a	MISSENSE	41271	41348	41422			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		41058	G=213	213	G	A						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
K113N	g.G339T	p.K113N			21901	S	S	MISSENSE	1	1	41422						0	T=1	1	T	G						False	Q.1	Q.1=True	de_escalated		18-Dec-2020	
K120N	g.G360T	p.K120N			625	ORF1ab	ORF1a	MISSENSE	41327	41348	41422			leader protein	nsp1, produced by both pp1a and pp1ab		41118	T=209	209	T	G						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
K1343T	g.A4028C	p.K1343T			4293	ORF1ab	ORF1a	MISSENSE	41317	41348	41422			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		40400	C=917	917	C	A						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
K3215K	g.G9645A	p.K3215K			9910	ORF1ab	ORF1a	SILENT	41314	41348	41422			nsp4	nsp4B_TM, contains transmembrane domain 2 (TM2), produced by both pp1a and pp1ab		34560	A=6754	6754	A	G						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
K3353R	g.A10058G	p.K3353R			10323	ORF1ab	ORF1a	MISSENSE	41319	41348	41422			3C-like proteinase	nsp5A_3CLpro and nsp5B_3CLpro, main proteinase (Mpro), mediates cleavages downstream of nsp4. 3D structure of the SARSr-CoV homolog has been determined (Yang et al., 2003), produced by both pp1a and pp1ab		40958	G=361	361	G	A						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
K373N	g.G1119T	p.K373N			29392	N	N	MISSENSE	63	64	41422						62	T=1	1	T	G						False	Q.4	Q.4=False	de_escalated		18-Dec-2020	
K47R	g.A140G	p.K47R			405	ORF1ab	ORF1a	MISSENSE	41331	41348	41422			leader protein	nsp1, produced by both pp1a and pp1ab		40789	G=542	542	G	A						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
K5784R	g.A17351G	p.K5784R			17615	ORF1ab	ORF1b	MISSENSE	41418	41421	41422			helicase	nsp13_ZBD, nsp13_TB, and nsp_HEL1core, zinc-binding domain (ZD), NTPase/helicase domain (HEL), RNA 5'-triphosphatase, produced by pp1ab only		37404	G=4013	4013	G	A						False	B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=True, B.1.1.7=False	de_escalated		18-Dec-2020	
K6561N	g.G19683T	p.K6561N			19947	ORF1ab	ORF1b	MISSENSE	64	64	41422			endoRNAse	nsp15-A1 and nsp15B-NendoU, produced by pp1ab only		61	T=3	3	T	G						False	Q.4	Q.4=False	de_escalated		18-Dec-2020	
K68X	g.A202T	p.K68X			28095	ORF8	ORF8	NONSENSE	40242	41348	41422						12822	T=27420	27420	T	A						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
K6958R	g.A20873G	p.K6958R			21137	ORF1ab	ORF1b	MISSENSE	41059	41348	41422			2'-O-ribose methyltransferase	nsp16_OMT, 2'-o-MT, produced by pp1ab only		39485	G=1574	1574	G	A						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
L140L	g.C418T	p.L140L			683	ORF1ab	ORF1a	SILENT	41391	41412	41422			leader protein	nsp1, produced by both pp1a and pp1ab		41060	T=331	331	T	C						False	B.1.1.7, Q.4	Q.4=False, B.1.1.7=False	de_escalated		18-Dec-2020	
L15F	g.G45T	p.L15F			25437	ORF3a	ORF3a	MISSENSE	41330	41348	41422						39395	T=1932	1932	T	G						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
L1643L	g.C4927T	p.L1643L			5192	ORF1ab	ORF1a	SILENT	37	64	41422			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		36	T=1	1	T	C						False	Q.4	Q.4=False	de_escalated		18-Dec-2020	
L176F	g.C526T	p.L176F			22088	S	S	MISSENSE	41240	41348	41422						39366	T=1873	1873	T	C						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
L1884L	g.G5652A	p.L1884L			5917	ORF1ab	ORF1a	SILENT	64	64	41422			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		63	A=1	1	A	G						False	Q.4	Q.4=False	de_escalated		18-Dec-2020	
L216F	g.C646T	p.L216F			22208	S	S	MISSENSE	41242	41348	41422						40305	T=937	937	T	C						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
L219F	g.C655T	p.L219F			28928	N	N	MISSENSE	41300	41348	41422						40985	T=315	315	T	C						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
L2874L	g.A8622G	p.L2874L			8887	ORF1ab	ORF1a	SILENT	63	64	41422	mask	single_src,highly_homoplasic	nsp4	nsp4B_TM, contains transmembrane domain 2 (TM2), produced by both pp1a and pp1ab		60	G=3	3	G	A						False	Q.4	Q.4=False	de_escalated		18-Dec-2020	
L29F	g.C85T	p.L29F			26607	M	M	MISSENSE	41318	41348	41422						41087	T=229	229	T	C						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
L3116F	g.C9346T	p.L3116F			9611	ORF1ab	ORF1a	MISSENSE	41323	41348	41422			nsp4	nsp4B_TM, contains transmembrane domain 2 (TM2), produced by both pp1a and pp1ab		40737	T=586	586	T	C						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
L3198L	g.C9592T	p.L3198L			9857	ORF1ab	ORF1a	SILENT	41297	41348	41422			nsp4	nsp4B_TM, contains transmembrane domain 2 (TM2), produced by both pp1a and pp1ab		40724	T=573	573	T	C						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
L3606F	g.G10818T	p.L3606F			11083	ORF1ab	ORF1a	MISSENSE	41303	41348	41422	mask	highly_homoplasic	nsp6	nsp6_TM, putative transmembrane domain, produced by both pp1a and pp1ab		40875	T=428	428	T	G						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
L3796L	g.C11388T	p.L3796L			11653	ORF1ab	ORF1a	SILENT	64	64	41422			nsp6	nsp6_TM, putative transmembrane domain, produced by both pp1a and pp1ab		63	T=1	1	T	C						False	Q.4	Q.4=False	de_escalated		18-Dec-2020	
L3829F	g.C11485T	p.L3829F			11750	ORF1ab	ORF1a	MISSENSE	41252	41348	41422			nsp6	nsp6_TM, putative transmembrane domain, produced by both pp1a and pp1ab		37332	T=3917	3917	T	C						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
L3900L	g.A11700G	p.L3900L			11965	ORF1ab	ORF1a	SILENT	41319	41348	41422			nsp7	produced by both pp1a and pp1ab		40397	G=922	922	G	A						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
L4182F	g.C12544T	p.L4182F			12809	ORF1ab	ORF1a	MISSENSE	41320	41348	41422			nsp9	ssRNA-binding protein, produced by both pp1a and pp1ab		39748	T=1572	1572	T	C						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
L4779L	g.C14335T	p.L4779L			14599	ORF1ab	ORF1b	SILENT	41346	41348	41422			RNA-dependent RNA polymerase	nsp12, NiRAN and RdRp, produced by pp1ab only		41076	T=270	270	T	C						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
L5619L	g.C16855T	p.L5619L			17119	ORF1ab	ORF1b	SILENT	41347	41348	41422			helicase	nsp13_ZBD, nsp13_TB, and nsp_HEL1core, zinc-binding domain (ZD), NTPase/helicase domain (HEL), RNA 5'-triphosphatase, produced by pp1ab only		40395	T=952	952	T	C						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
L578L	g.C1732T	p.L578L			1997	ORF1ab	ORF1a	SILENT	41332	41348	41422			nsp2	produced by both pp1a and pp1ab		41039	T=293	293	T	C						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
L5F	g.C13T	p.L5F			21575	S	S	MISSENSE	40814	41349	41422	mask	highly_homoplasic				36674	T=4140	4140	T	C	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.1x decrease in binding (KD) relative to D614G.	False	Q.1, B.1.1.7	B.1.1.7=False, Q.1=True	de_escalated		18-Dec-2020	
L5F	g.C13T	p.L5F			21575	S	S	MISSENSE	40814	41349	41422	mask	highly_homoplasic				36674	T=4140	4140	T	C	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	No change in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	Q.1, B.1.1.7	B.1.1.7=False, Q.1=True	de_escalated		18-Dec-2020	
L5F	g.C13T	p.L5F			21575	S	S	MISSENSE	40814	41349	41422	mask	highly_homoplasic				36674	T=4140	4140	T	C	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	1.23x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.1x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	Q.1, B.1.1.7	B.1.1.7=False, Q.1=True	de_escalated		18-Dec-2020	
L6336V	g.T19006G	p.L6336V			19270	ORF1ab	ORF1b	MISSENSE	63	64	41422			3'-to-5' exonuclease	nsp14A2_ExoN and nsp14B_NMT, produced by pp1ab only		7	G=56	56	G	T						False	Q.4	Q.4=True	de_escalated		18-Dec-2020	
L6420L	g.C19260T	p.L6420L			19524	ORF1ab	ORF1b	SILENT	39061	41349	41422			3'-to-5' exonuclease	nsp14A2_ExoN and nsp14B_NMT, produced by pp1ab only		35473	T=3588	3588	T	C						False	Q.1, B.1.1.7	B.1.1.7=False, Q.1=True	de_escalated		18-Dec-2020	
L730F	g.C2188T	p.L730F			2453	ORF1ab	ORF1a	MISSENSE	41327	41348	41422			nsp2	produced by both pp1a and pp1ab		40155	T=1172	1172	T	C						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
L730L	g.C2190T	p.L730L			2455	ORF1ab	ORF1a	SILENT	41329	41348	41422			nsp2	produced by both pp1a and pp1ab		40347	T=982	982	T	C						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
M1586I	g.G4758A	p.M1586I			5022	ORF1ab	ORF1a	MISSENSE	9	9	41422			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		0	CA=3	3	CA	TG						False	Q.3	Q.3=False	de_escalated		18-Dec-2020	
M1586T	g.TG4757_4758CA	p.M1586T			5022	ORF1ab	ORF1a		9	9	41422			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		0	TA=6	6	TA	TG						False	Q.3	Q.3=False	de_escalated		18-Dec-2020	
M1fs	g.1delA	p.M1fs			28270	N	intergenic		40846	41422	41422			(N|GU280_gp10|1|1.00)			1135	TAAATG=39693	39693	TAAATG	TAAAATG						False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=True, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
M2259I	g.G6777T	p.M2259I			7042	ORF1ab	ORF1a	MISSENSE	41285	41348	41422			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		35835	T=5450	5450	T	G						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
M2365I	g.G7095T	p.M2365I			7360	ORF1ab	ORF1a	MISSENSE	64	64	41422			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		53	T=11	11	T	G						False	Q.4	Q.4=False	de_escalated		18-Dec-2020	
M4855I	g.G14565T	p.M4855I			14829	ORF1ab	ORF1b	MISSENSE	64	64	41422			RNA-dependent RNA polymerase	nsp12, NiRAN and RdRp, produced by pp1ab only		60	T=4	4	T	G						False	Q.4	Q.4=False	de_escalated		18-Dec-2020	
N121N	g.C363T	p.N121N			26885	M	M	SILENT	64	64	41422						7	T=57	57	T	C						False	Q.4	Q.4=True	de_escalated		18-Dec-2020	
N1439N	g.C4317T	p.N1439N			4582	ORF1ab	ORF1a	SILENT	41300	41348	41422			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		35472	T=5828	5828	T	C						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
N1749N	g.C5247T	p.N1749N			5512	ORF1ab	ORF1a	SILENT	41191	41348	41422			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		40851	T=340	340	T	C						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
N1922N	g.C5766T	p.N1922N			6031	ORF1ab	ORF1a	SILENT	41178	41348	41422			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		40956	T=222	222	T	C						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
N2038N	g.T6114C	p.N2038N			6379	ORF1ab	ORF1a	SILENT	41310	41348	41422			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		41098	C=212	212	C	T						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
N2147N	g.C6441T	p.N2147N			6706	ORF1ab	ORF1a	SILENT	41330	41348	41422			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		40892	T=438	438	T	C						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
N2405N	g.T7215C	p.N2405N			7480	ORF1ab	ORF1a	SILENT	64	64	41422			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		63	C=1	1	C	T						False	Q.4	Q.4=False	de_escalated		18-Dec-2020	
N3291N	g.C9873T	p.N3291N			10138	ORF1ab	ORF1a	SILENT	64	64	41422			3C-like proteinase	nsp5A_3CLpro and nsp5B_3CLpro, main proteinase (Mpro), mediates cleavages downstream of nsp4. 3D structure of the SARSr-CoV homolog has been determined (Yang et al., 2003), produced by both pp1a and pp1ab		62	T=2	2	T	C						False	Q.4	Q.4=False	de_escalated		18-Dec-2020	
N3347S	g.A10040G	p.N3347S			10305	ORF1ab	ORF1a	MISSENSE	64	64	41422			3C-like proteinase	nsp5A_3CLpro and nsp5B_3CLpro, main proteinase (Mpro), mediates cleavages downstream of nsp4. 3D structure of the SARSr-CoV homolog has been determined (Yang et al., 2003), produced by both pp1a and pp1ab		63	G=1	1	G	A						False	Q.4	Q.4=False	de_escalated		18-Dec-2020	
N343N	g.C1029T	p.N343N			22591	S	S	SILENT	41170	41348	41422						40408	T=762	762	T	C						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
N3537S	g.A10610G	p.N3537S			10875	ORF1ab	ORF1a	MISSENSE	41028	41348	41422			3C-like proteinase	nsp5A_3CLpro and nsp5B_3CLpro, main proteinase (Mpro), mediates cleavages downstream of nsp4. 3D structure of the SARSr-CoV homolog has been determined (Yang et al., 2003), produced by both pp1a and pp1ab		40716	G=311	311	G	A						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
N4889N	g.C14667T	p.N4889N			14931	ORF1ab	ORF1b	SILENT	41343	41348	41422			RNA-dependent RNA polymerase	nsp12, NiRAN and RdRp, produced by pp1ab only		40986	T=357	357	T	C						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
N4944N	g.T14832C	p.N4944N			15096	ORF1ab	ORF1b	SILENT	41282	41348	41422			RNA-dependent RNA polymerase	nsp12, NiRAN and RdRp, produced by pp1ab only		28391	C=12891	12891	C	T						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	41170	41422	41422						2	T=41168	41168	T	A	ACE2 receptor binding affinity	Barton et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.05.18.444646v1		The N501Y mutation had the biggest effect on ACE2 affinity of any VOC mutation tested, increasing the affinity ~10 fold to KD ~7 nM, by increasing the k(on) ~1.8 fold and decreasing the k(off) by ~ 7 fold as measured by surface plasmon resonance. 	False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=True, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	41170	41422	41422						2	T=41168	41168	T	A	ACE2 receptor binding affinity	Collier et al. (2021)	https://www.nature.com/articles/s41586-021-03412-7		This combination showed ~3x increase binding to ACE2 vs wild type, about half that of the B.1.1.7 lineage, suggesting that the K417N mutation is slightly detrimental to ACE2 binding, probably as a result of disrupting the salt bridge formed with ACE2 residue D30	False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=True, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	41170	41422	41422						2	T=41168	41168	T	A	ACE2 receptor binding affinity	Gamez et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.09.439154v1		The most frequent RBM mutation N501Y (165,519 instances) makes defective the atypical N-glycosylation  sequon NGV 501-503, becoming a key RBM position for the interaction with hACE2-binding hotspot 353.	False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=True, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	41170	41422	41422						2	T=41168	41168	T	A	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	"Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 2.52x increase in binding (KD) relative to D614G, mostly due to decreased in ""off-rate"" a.k.a. dissociation rate (Kdis). Compare to full Spike variant complements for major lineages containing this variant subset: 5.43x (B.1.1.7 aka Alpha), 3.56x (B.1.351 aka Beta), 4.24x (P.1 aka Gamma)."	False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=True, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	41170	41422	41422						2	T=41168	41168	T	A	ACE2 receptor binding affinity	Laffeber et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.22.432357v1		RBD containing the N501Y mutation results in 9-fold stronger binding to the hACE2 receptor than  wild type RBD. The E484K mutation does not significantly influence the affinity for the receptor,  while K417N attenuates affinity. As a result, RBD from B.1.351 containing all three mutations binds  3-fold stronger to hACE2 than wild type RBD but 3-fold weaker than N501Y.	False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=True, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	41170	41422	41422						2	T=41168	41168	T	A	ACE2 receptor binding affinity	Liu et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.02.428884v1		Reported 10-fold increase in ACE2 binding vs wildtype (Kd 	False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=True, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	41170	41422	41422						2	T=41168	41168	T	A	ACE2 receptor binding affinity	Liu et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.16.431305v1		Studying the key covariants in lineage of concern 501Y.V2,  observed about 2-fold increase in ACE2 binding vs wildtype, but greatly decreased mAb binding, suggesting evolutionary optimum tension between  immune evasion and ACE2 binding affinity as the N501Y variant alone has 10x increase in affinity but no effect on tested mAb binding.	False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=True, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	41170	41422	41422						2	T=41168	41168	T	A	ACE2 receptor binding affinity	Motozono et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.02.438288v1		~4-fold increase in binding affinity vs wild type.	False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=True, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	41170	41422	41422						2	T=41168	41168	T	A	ACE2 receptor binding affinity	Ramanathan et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.22.432359v1		Using Microscale Thermopheresis, this variant binds ACE2 at nearly  two-fold greater affinity than the original SARS-COV-2 RBD (203.7 nM vs 402.5 nM).	False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=True, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	41170	41422	41422						2	T=41168	41168	T	A	ACE2 receptor binding affinity	Ramanathan et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.22.432359v1		Using Mircoscale Thermopheresis, the B.1.351 variant harboring three mutations, binds ACE2 at nearly  five-fold greater affinity than the original SARS-COV-2 RBD (Kd 87.6, vs 402.5 nM).	False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=True, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	41170	41422	41422						2	T=41168	41168	T	A	ACE2 receptor binding affinity	Santos and Passos (2021)	https://www.biorxiv.org/content/10.1101/2020.12.29.424708v1		In silico methods (PyMOL and PDBePISA) involving mutagenesis (N501Y mutation) and interface analysis focusing on the Spike  RDB-ACE2 interaction showed that the SARS-CoV-2 N501Y mutant (lineage B.1.1.7) establishes a more significant number of  interactions relating to the mutant residue Y501 (Spike RDB) with residues Y41 and K353 (ACE2). This finding shows that the  increased infectivity of SARS-CoV-2 lineage B.1.1.7 is associated with the interaction force between the Spike RBD Y501  mutant residue with the ACE2 receptor, which in this strain is increased.	False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=True, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	41170	41422	41422						2	T=41168	41168	T	A	ACE2 receptor binding affinity	Starr et al. (2020)	https://doi.org/10.1016/j.cell.2020.08.012		Experimentally, ACE2 binding affinity increased 0.24 fold	False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=True, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	41170	41422	41422						2	T=41168	41168	T	A	ACE2 receptor binding affinity	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1		This single mutation causes major increase in binding affinity vs. wild type as measured by IC50 vs pseudotyped lentivirus,  but combined with the complete set of B.1.1.7   lineage variants no major change vs wild type affnity is observed. 	False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=True, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	41170	41422	41422						2	T=41168	41168	T	A	ACE2 receptor binding affinity	Tian et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.14.431117v2		Reported 4-fold increase in affinity compared to wild-type RBD on the cell surface (Kd 	False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=True, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	41170	41422	41422						2	T=41168	41168	T	A	ACE2 receptor binding affinity	Tian et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.14.431117v2		Reported slight increase in affinity compared to wild-type RBD on the cell surface (Kd 	False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=True, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	41170	41422	41422						2	T=41168	41168	T	A	ACE2 receptor binding affinity	Vogel et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.04.433887v1		The affinity of ACE2 for this mutation combination was twice as high as for wild type. Having in mind that the affinity of SARS-CoV-2 for ACE2 is only 4-fold higher compared to SARS-CoV-1, this factor of 2 is expected to be biologically significant.	False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=True, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	41170	41422	41422						2	T=41168	41168	T	A	ACE2 receptor binding affinity	Zahradnik et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.06.425392		Among the first selected and fixed variants in an in vitro evolution experiment for ACE2 binding. Calculated disassociation constant for this variant is nearly four fold lower than wild type (Kd 	False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=True, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	41170	41422	41422						2	T=41168	41168	T	A	ACE2 receptor binding affinity	Zhu et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.11.426269v2		N501Y residue inserts into a cavity at the binding interface near Y41 of ACE2.  The additional interactions result in increased affinity of ACE2 for the N501Y mutant,  accounting for its increased infectivity.	False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=True, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	41170	41422	41422						2	T=41168	41168	T	A	T cell evasion	Reynolds et al. (2021)	https://science.sciencemag.org/content/early/2021/04/29/science.abh1282		Vaccinated, but not post-infection sera, show decreased average T cell response to an N501Y peptide. When we primed transgenic mice expressing human HLA-DRB1*0401 with the Wuhan Hu-1 peptide pool,  T cell responses to the B.1.1.7 variant peptide pool were significantly reduced (p 	False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=True, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	41170	41422	41422						2	T=41168	41168	T	A	antibody epitope effects	Chen et al. (2021)	https://www.nature.com/articles/s41591-021-01294-w 		Ablates Class 3 N-terminal domain targeting antibody COV2-2489, diminishes COV2-2676.	False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=True, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	41170	41422	41422						2	T=41168	41168	T	A	antibody epitope effects	Collier et al. (2021)	https://www.nature.com/articles/s41586-021-03412-7		Of 50 mAbs tested, major loss of neutralization observed for S2X128, S2D8, S2X192, S2D19, S2H14, S2H19.	False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=True, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	41170	41422	41422						2	T=41168	41168	T	A	antibody epitope effects	Haynes et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.01.06.20248960v1		Wildtype elicits immune response, COVID-19 cohort epitope score > 99th percentile of the 497 pre-pandemic controls, mutant drops PIWAS epitope score from 3% to 1.2% (poorer immune recognition) Together with other B1.1.7 lineage mutational changes (Spike: Y144del, A570D, P681H, Nucleoprotein: D3L, S235F) resulted in only 2 or 579 individuals (0.3% of the population) having a dramatic reduction in PIWAS antigen scores, which reflects the peak epitope signal along the entire antigen.	False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=True, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	41170	41422	41422						2	T=41168	41168	T	A	antibody epitope effects	Klegerman et al. (2021)	https://doi.org/10.1101/2021.04.26.441517		Contrary to other reports on N501Y containing lineages (i.e. with additional mutations), N501Y alone may have an even greater affinity for a human monoclonal antibody specific for wild type. These results suggest that the individual N501Y mutation does not contribute to altered viral properties by itself, but may contribute to a collective conformational shift produced by multiple mutations.	False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=True, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	41170	41422	41422						2	T=41168	41168	T	A	antibody epitope effects	Rees-Spear et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.15.426849v1		Lowered the neutralization potency of mAb COVA1-12 to the limit of the assay. Decrease in potency was observed against the N501Y pseudotype for the cluster IX mAb COVA2-17.	False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=True, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	41170	41422	41422						2	T=41168	41168	T	A	antibody epitope effects	Shen et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.27.428516v2		Reduction in neutralization by mAbs COVA1-18 (~4x), COVA2-15 (~9x), S309 (~3x)	False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=True, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	41170	41422	41422						2	T=41168	41168	T	A	antibody epitope effects	Wang et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2		4 antibodies tested were less potent against K417N by ten-fold or more, in both mAb classes 1 and 3	False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=True, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	41170	41422	41422						2	T=41168	41168	T	A	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	1.65x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=True, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	41170	41422	41422						2	T=41168	41168	T	A	convalescent plasma escape	Cele et al. (2021)	https://www.krisp.org.za/manuscripts/MEDRXIV-2021-250224v1-Sigal.pdf		The 501Y.V2 to first wave IC50 ratio ranged from 6 to 200-fold. Averaging across all 7 participant convalescent sera highlighted the dramatic decrease in sensitivity to neutralization of authentic 501Y.V2 variants. PG: I'm purposefully ignoring D614G and A701V as contributors	False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=True, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	41170	41422	41422						2	T=41168	41168	T	A	convalescent plasma escape	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008		0.7x reduction in neutralization by key variant in several variants of concern in sera collected from cohort of 10 with severe  disease 21 to 63 days post-onset. 	False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=True, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	41170	41422	41422						2	T=41168	41168	T	A	convalescent plasma escape	Rathnasinghe et al. (2021)	https://dx.doi.org/10.1101%2F2021.01.19.21249592		In 30 samples collected 111 to 260 days post onset of symptoms, the covalescent plasma can neutralize both  the reference USA-WA1/2020 strain and the mouse adapted strain that contains the N501Y spike mutation with similar efficiency.	False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=True, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	41170	41422	41422						2	T=41168	41168	T	A	convalescent plasma escape	Shen et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.27.428516v2		Neutralization activity of convalescent sera tested decreased ~2x with this B.1.1.7 pseudotyped virus.	False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=True, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	41170	41422	41422						2	T=41168	41168	T	A	convalescent plasma escape	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1		Viruses containing the point mutations of B.1.1.7 showed that the single point mutations (Δ69-70 and N501Y) were neutralized as efficiently as D614G across 10 convalescent sera from April 2020 infectees.	False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=True, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	41170	41422	41422						2	T=41168	41168	T	A	convalescent plasma escape	Tang et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.19.436183v1		As measured by surface plasmon resonance, RBD with the N501Y mutation alone showed a mean 2.1x decrease in binding affinity for  six batches of hyperimmune immunoglobulin (hCoV-2IG) preparations generated from SARS-CoV-2 convalescent plasma.	False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=True, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	41170	41422	41422						2	T=41168	41168	T	A	convalescent plasma escape	Wibmer et al. (2021)	https://doi.org/10.1101/2021.01.18.427166		"27% of 44 early pandemic exposure convalescent plasma/sera lose all activity against a RBD triple mutant pseudovirus (RBD mutatants of the 501Y.V2 ""South African"" lineage), while only 23% retained high titres "	False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=True, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	41170	41422	41422						2	T=41168	41168	T	A	convalescent plasma escape	Wibmer et al. (2021)	https://doi.org/10.1101/2021.01.18.427166		"Nearly half (21 of 44, 48%) of early pandemic exposure convalescent plasma/sera failed to neutralize the 501Y.V2 (""South African"") lineage pseudovirus construct Only 3 of 44 convascent sera (those with the highest titer, which correlated direectly with initial infection severity) had high neutralization against this 501Y.V2  PG: note that lineage variant R246I was excluded from the text in reference to these sera assays, not sure if that was an oversight."	False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=True, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	41170	41422	41422						2	T=41168	41168	T	A	environmental condition stability	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1		Relative to D614G, this mutation demonstrated significant increase in infectivity (i.e. heat stability) after incubation at 50C after 30 minutes or 1 hour	False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=True, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	41170	41422	41422						2	T=41168	41168	T	A	homoplasy	Flores-Alanis et al. (2021)	https://www.mdpi.com/2076-0817/10/2/184/htm		Variant within the six key residues in the receptor binding domain (RBD). Independently reported in UK, Australia  (same origin as UK), and South Africa (independent origin).	False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=True, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	41170	41422	41422						2	T=41168	41168	T	A	immunosuppression variant emergence	Choi et al. (2020)	https://www.nejm.org/doi/full/10.1056/NEJMc2031364		Appeared (day 128) and persisted in chronic (152 day) SARS-CoV-2 infection of immunocompromised patient with severe antiphospholipid syndrome	False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=True, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	41170	41422	41422						2	T=41168	41168	T	A	monoclonal antibody serial passage escape	Wang et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2		In vitro selection against class 1 (Spike 'up' conformation) monoclonal antibody C663, and to a lesser extent C613.	False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=True, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	41170	41422	41422						2	T=41168	41168	T	A	pharmaceutical effectiveness	Engelhart et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1		COR-101 lost ~8x binding against this isolated mutation. Regdanvimab lost ~6x binding against this isolated mutation.	False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=True, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	41170	41422	41422						2	T=41168	41168	T	A	pharmaceutical effectiveness	Engelhart et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1		Tixagevimab, Regdanvimab and COR-101 display reduced binding affinity to virus pseudotyped as RBD from B.1.351.	False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=True, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	41170	41422	41422						2	T=41168	41168	T	A	pharmaceutical effectiveness	Liu et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.16.431305v1		This mutated version of RBD completely abolishes the binding to a therapeutic antibody, Bamlanivimab, in vitro.	False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=True, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	41170	41422	41422						2	T=41168	41168	T	A	reinfection	Novazzi et al. (2021)	https://doi.org/10.1002/jmv.27066	'A570D'	Partial sequencing of S gene reveals two cases of probable early 2021 B.1.1.7 lineage reinfection from non-B.1.1.7 original cases in Lombardy, with 45 to 90 days between infections (less than the typical 90 day guideline for this call). Patients were 56 and 58yo, immunocompenent, with one a former smoker with obesity and dyslipidemia. One case required intubation during first infection,  but presented with mild symptoms upon reinfection. The other case convalesced at home during the first episode, but required CPAP support  in the subacute clinical unit upon reinfection.	False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=True, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	41170	41422	41422						2	T=41168	41168	T	A	syncytium formation	Kim et al. (2021)	https://dx.doi.org/10.3390%2Fv13040633	'D614G'	Slight increase in Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus relative to wild type, no change relative to D614G.	False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=True, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	41170	41422	41422						2	T=41168	41168	T	A	trafficking	Kim et al. (2021)	https://dx.doi.org/10.3390%2Fv13040633	'D614G'	More efficient infectivity (24h) compared to wild type, in Caco-2 cells ~9x, Vero ~8x, and Calu-3 ~8x. Compare to wild type at ~5x across cell types.	False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=True, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	41170	41422	41422						2	T=41168	41168	T	A	trafficking	Kim et al. (2021)	https://dx.doi.org/10.3390%2Fv13040633	'D614G'	~4x more efficient S2 domain cleavage compared to wild type, no change relative to D614G alone in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3).	False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=True, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	82266	82844	41422						4	T=82262	82262	T	A	trafficking	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'D614G'	9x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.	False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=True, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	41170	41422	41422						2	T=41168	41168	T	A	trafficking	Motozono et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.02.438288v1		Decreased stability of RBD expression in yeast, suggesting decreased Spike protein stability.	False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=True, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	41170	41422	41422						2	T=41168	41168	T	A	trafficking	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1		Lentiviral pseudotyped with this individual mutation from B.1.1.7 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing slightly increased infection rate amongst the cells.  [in what is essentially a replicate experiment in the same paper, because  each B.1.351 lineage variant was independetly evaluated and N501 is in both lineages,  a significant decrease was observed, therefore the error bars described in this paper should be interpreted carefully]	False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=True, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	41170	41422	41422						2	T=41168	41168	T	A	vaccine neutralization efficacy	Bates et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.04.04.21254881v1		Observed 1.3-fold reduction in neutralization efficiency of Pfizer vaccinee sera (collected 14 days after second dose)  against pseudotype B.1.1.7 key variant lentivirus. Compare to 2.6-fold reduction against cultured B.1.1.7 virus.	False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=True, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	41170	41422	41422						2	T=41168	41168	T	A	vaccine neutralization efficacy	Edara et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.02.02.21250799v1		1.2x drop in neutralization using sera collected from 14 healthy adult participants that received two injections of the mRNA-1273 (Moderna) vaccine  at a dose of 100 µg (18-55 years: day 1 and day 14 post-2nd dose) against a recombinant single variant virus (modified replicating WA-1 cDNA clone)  relative to contemporary circulating D614G variant (USA/GA-EHC-083E/2020) using a live-virus Focus Reduction Neutralization Test (FRNT) assay. 	False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=True, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	41170	41422	41422						2	T=41168	41168	T	A	vaccine neutralization efficacy	Jacobson et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.04.14.21255431v2		The presence of this variant in 189 post-mRNA-vaccination COVID-19 cases was proportionally in line with lineage prevalence in Northen California during the study period, suggesting no effect of these variants on immune escape.	False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=True, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	41170	41422	41422						2	T=41168	41168	T	A	vaccine neutralization efficacy	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'D614G'	This variant showed no change in Pfizer sera (one or two dose) neutralization efficiency vs D614G (using lentivirus pseudotype).	False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=True, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	41170	41422	41422						2	T=41168	41168	T	A	vaccine neutralization efficacy	Rathnasinghe et al. (2021)	https://dx.doi.org/10.1101%2F2021.01.19.21249592		Human sera from 6 two-dose Pfizer vaccinated individuals (47-68 days post 1st-dose) can neutralize both the reference  USA-WA1/2020 strain and the mouse adapted SARS-CoV-2 strain that contains the N501Y spike mutation with similar efficiency.	False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=True, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	41170	41422	41422						2	T=41168	41168	T	A	vaccine neutralization efficacy	Wang et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2		In a cohort of 20 patients 8+ weeks after second vaccine dose of Moderna (mRNA-1273) or Pfizer-BioNTech (BNT162b2) vaccines,  a modest decrease in neutralization by vaccine plasma was observed.	False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=True, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	41170	41422	41422						2	T=41168	41168	T	A	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	1.17x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.09x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=True, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	41170	41422	41422						2	T=41168	41168	T	A	virion structure	Spratt et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1		Estimated free energy change (ddG) for this variant is 0.69 kcal/mol (i.e. stabilizing relative to wild type) 	False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=True, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
N540S	g.A1619G	p.N540S			23181	S	S	MISSENSE	41296	41348	41422						40430	G=866	866	G	A						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
N615N	g.C1845T	p.N615N			2110	ORF1ab	ORF1a	SILENT	41322	41348	41422			nsp2	produced by both pp1a and pp1ab		27534	T=13788	13788	T	C						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
N824N	g.C2472T	p.N824N			24034	S	S	SILENT	40888	41348	41422						39803	T=1085	1085	T	C						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
P104S	g.C310T	p.P104S			25702	ORF3a	ORF3a	MISSENSE	41331	41348	41422						41022	T=309	309	T	C						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
P122P	g.C366T	p.P122P			28639	N	N	SILENT	64	64	41422						57	T=7	7	T	C						False	Q.4	Q.4=False	de_escalated		18-Dec-2020	
P1330P	g.G3990A	p.P1330P			4255	ORF1ab	ORF1a	SILENT	41267	41348	41422			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		40547	A=717	717	A	G						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
P1921S	g.C5761T	p.P1921S			6026	ORF1ab	ORF1a	MISSENSE	41180	41348	41422			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		40820	T=360	360	T	C						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
P26T	g.C76A	p.P26T			21638	S	S	MISSENSE	64	64	41422						63	A=1	1	A	C						False	Q.4	Q.4=False	de_escalated		18-Dec-2020	
P309P	g.C927T	p.P309P			29200	N	N	SILENT	41251	41348	41422						41018	T=230	230	T	C						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
P4058P	g.C12174T	p.P4058P			12439	ORF1ab	ORF1a	SILENT	41306	41348	41422			nsp8	produced by both pp1a and pp1ab		39956	T=1350	1350	T	C						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
P4223L	g.C12668T	p.P4223L			12933	ORF1ab	ORF1a	MISSENSE	41318	41348	41422			nsp9	ssRNA-binding protein, produced by both pp1a and pp1ab		40658	T=660	660	T	C						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
P4561P	g.A13683G	p.P4561P			13947	ORF1ab	ORF1b	SILENT	41347	41348	41422			RNA-dependent RNA polymerase	nsp12, NiRAN and RdRp, produced by pp1ab only		40936	G=410	410	G	A						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
P4619L	g.C13856T	p.P4619L			14120	ORF1ab	ORF1b	MISSENSE	41340	41348	41422			RNA-dependent RNA polymerase	nsp12, NiRAN and RdRp, produced by pp1ab only		27550	T=13790	13790	T	C						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
P46L	g.C137T	p.P46L			28410	N	N	MISSENSE	64	64	41422						63	T=1	1	T	C						False	Q.4	Q.4=False	de_escalated		18-Dec-2020	
P4715L	g.C14144T	p.P4715L			14408	ORF1ab	ORF1b	MISSENSE	41411	41422	41422			RNA-dependent RNA polymerase	nsp12, NiRAN and RdRp, produced by pp1ab only		0	T=41411	41411	T	C						False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=True, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
P4804P	g.C14412T	p.P4804P			14676	ORF1ab	ORF1b	SILENT	41414	41422	41422			RNA-dependent RNA polymerase	nsp12, NiRAN and RdRp, produced by pp1ab only		0	T=41414	41414	T	C						False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=True, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
P5402S	g.C16204T	p.P5402S			16468	ORF1ab	ORF1b	MISSENSE	41280	41348	41422			helicase	nsp13_ZBD, nsp13_TB, and nsp_HEL1core, zinc-binding domain (ZD), NTPase/helicase domain (HEL), RNA 5'-triphosphatase, produced by pp1ab only		41068	T=212	212	T	C						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
P57L	g.C170T	p.P57L			27371	ORF6	ORF6	MISSENSE	64	64	41422						60	T=4	4	T	C						False	Q.4	Q.4=False	de_escalated		18-Dec-2020	
P6067P	g.T18201C	p.P6067P			18465	ORF1ab	ORF1b	SILENT	41290	41348	41422	caution	single_src,highly_ambiguous	3'-to-5' exonuclease	nsp14A2_ExoN and nsp14B_NMT, produced by pp1ab only		41061	C=229	229	C	T						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
P6252L	g.C18755T	p.P6252L			19019	ORF1ab	ORF1b	MISSENSE	41340	41348	41422			3'-to-5' exonuclease	nsp14A2_ExoN and nsp14B_NMT, produced by pp1ab only		40592	T=748	748	T	C						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
P6376S	g.C19126T	p.P6376S			19390	ORF1ab	ORF1b	MISSENSE	39569	41348	41422			3'-to-5' exonuclease	nsp14A2_ExoN and nsp14B_NMT, produced by pp1ab only		33055	T=6514	6514	T	C						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
P6657S	g.C19969T	p.P6657S			20233	ORF1ab	ORF1b	MISSENSE	40966	41348	41422			endoRNAse	nsp15-A1 and nsp15B-NendoU, produced by pp1ab only		40628	T=337	337	T	C						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
P681H	g.C2042A	p.P681H			23604	S	S	MISSENSE	40978	41422	41422						0	A=40972	40972	A	C	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.23x decrease in binding (KD) relative to D614G.	False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=True, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
P681H	g.C2042A	p.P681H			23604	S	S	MISSENSE	40978	41422	41422						0	A=40972	40972	A	C	antibody epitope effects	Chen et al. (2021)	https://www.nature.com/articles/s41591-021-01294-w 		Ablates Class 3 N-terminal domain targeting antibody COV2-2489, diminishes COV2-2676.	False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=True, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
P681H	g.C2042A	p.P681H			23604	S	S	MISSENSE	40978	41422	41422						0	A=40972	40972	A	C	antibody epitope effects	Haynes et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.01.06.20248960v1		Wildtype elicits immune response, COVID-19 cohort epitope score > 99th percentile of the 497 pre-pandemic controls, mutant drops PIWAS epitope score from 7.8% to 1.2% (significantly poorer immune recognition) Together with other B1.1.7 lineage mutational changes (Spike: Y144del,N501Y, A570D Nucleoprotein: D3L, S235F) resulted in only 2 of 579 individuals (0.3% of the population) having a dramatic reduction in PIWAS antigen scores, which reflects the peak epitope signal along the entire antigen.	False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=True, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
P681H	g.C2042A	p.P681H			23604	S	S	MISSENSE	40978	41422	41422						0	A=40972	40972	A	C	antibody epitope effects	Johnson et al. (2020)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7457603/ 		This variant is adjacent to the Spike protein furin cleavage site (cleavage of S into S1 and S2 subunits is required for viral membrane fusion and subsequent entry into host cells), a site shown to be highly immunogenic.	False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=True, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
P681H	g.C2042A	p.P681H			23604	S	S	MISSENSE	40978	41422	41422						0	A=40972	40972	A	C	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	1.26x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=True, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
P681H	g.C2042A	p.P681H			23604	S	S	MISSENSE	40978	41422	41422						0	A=40972	40972	A	C	trafficking	Lubinski et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.06.438731v1		While the introduction of P681H in the SARS-CoV-2 B.1.1.7 variant may increase spike cleavage by furin-like proteases,  this does not significantly impact viral entry or cell-cell spread. We consider that other factors are at play to account  for the increased in transmission and disease severity attributed to this variant of concern (VOC).	False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=True, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
P681H	g.C2042A	p.P681H			23604	S	S	MISSENSE	40978	41422	41422						0	A=40972	40972	A	C	trafficking	Maaroufi (2021)	https://www.researchgate.net/publication/348943694_The_mutation_P681H_in_the_B117_variant_of_SARS-CoV-2_probably_enhances_viral_entry_and_replication		This mutation in the first base of the furin clevage site maintains the RXXR recognition motif, and is presumed to enhance cleavage based on the removal of a proline-directed phosphotase recognition site at S680. In a homologuous site in Infectious  Bronchitis Virus (IBV, Gammacoronaviruses), abolition of S680 phosphorylation improves furin cleavage  (and presumably cell entry).	False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=True, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
P681H	g.C2042A	p.P681H			23604	S	S	MISSENSE	40978	41422	41422						0	A=40972	40972	A	C	trafficking	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1		Lentiviral pseudotyped with this individual mutation from B.1.1.7 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing NO statistically significant infection rate change amongst the cells, suggesting that furin cleavage typically used for cell entry is not affected by this change one  amino acid upstream of the RXXR recognition pattern. 	False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=True, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
P681H	g.C2042A	p.P681H			23604	S	S	MISSENSE	40978	41422	41422						0	A=40972	40972	A	C	vaccine neutralization efficacy	Zuckerman et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.03.25.21253908v1	'D614G'	No significant change in virus neutralzation by 18 Pfizer two dose vaccinee sera compared to B.1.1.7. [results without including the used mutation A27S likely generalizable, as this is not a lineage defining mutation]	False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=True, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
P681H	g.C2042A	p.P681H			23604	S	S	MISSENSE	40978	41422	41422						0	A=40972	40972	A	C	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	1.14x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.11x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=True, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
P681H	g.C2042A	p.P681H			23604	S	S	MISSENSE	40978	41422	41422						0	A=40972	40972	A	C	virion structure	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1		The Ratio of S2 (processed Spike) to full length Spike is higher for this mutation,  due to a drop in the full length Spike measured, suggesting that this mutation compensates for decreased Spike production by improved proteolytic processing.	False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=True, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
P681R	g.C2042G	p.P681R			23604	S	S	MISSENSE	64	64	41422						0	G=3	3	G	C	trafficking	Maaroufi (2021)	https://www.researchgate.net/publication/348943694_The_mutation_P681H_in_the_B117_variant_of_SARS-CoV-2_probably_enhances_viral_entry_and_replication		This mutation in the first base of the furin clevage site maintains the RXXR recognition motif, and is presumed to enhance cleavage based on the removal of a proline-directed phosphotase recognition site at S680. In a homologuous site in Infectious  Bronchitis Virus (IBV, Gammacoronaviruses), abolition of S680 phosphorylation improves furin cleavage  (and presumably cell entry). [Inference from similar positively charged substitution P681H actually described in the work]	False	Q.4	Q.4=False	de_escalated		18-Dec-2020	
P681R	g.C2042G	p.P681R			23604	S	S	MISSENSE	64	64	41422						0	G=3	3	G	C	trafficking	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.05.14.444076v1	'D614G'	Quantification of the band intensities showed that the P681R mutation, which lies near the proteolytic processing site,  caused a small increase in proteolytic processing as measured by a 2-fold decrease in the ratio of S/S2.	False	Q.4	Q.4=False	de_escalated		18-Dec-2020	
P681R	g.C2042G	p.P681R			23604	S	S	MISSENSE	64	64	41422						0	G=3	3	G	C	virion structure	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1		The Ratio of S2 (processed Spike) to full length Spike is higher for this mutation,  due to a drop in the full length Spike measured, suggesting that this mutation compensates for decreased Spike production by improved proteolytic processing. [PG: Inferred by conservative AA substitution of described P681H]	False	Q.4	Q.4=False	de_escalated		18-Dec-2020	
P6888P	g.T20664A	p.P6888P			20928	ORF1ab	ORF1b	SILENT	64	64	41422			2'-O-ribose methyltransferase	nsp16_OMT, 2'-o-MT, produced by pp1ab only		63	A=1	1	A	T						False	Q.4	Q.4=False	de_escalated		18-Dec-2020	
P971L	g.C2912T	p.P971L			3177	ORF1ab	ORF1a	MISSENSE	41338	41348	41422			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		41107	T=231	231	T	C						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
PR7013LN	g.CACG21038_21041TAAA	p.PR7013LN			21302	ORF1ab	ORF1b		40160	41349	41422			2'-O-ribose methyltransferase	nsp16_OMT, 2'-o-MT, produced by pp1ab only		37011	TAAA=3099	3099	TAAA	CACG						False	Q.1, B.1.1.7	B.1.1.7=False, Q.1=True	de_escalated		18-Dec-2020	
Q1592Q	g.A4776G	p.Q1592Q			5041	ORF1ab	ORF1a	SILENT	40942	41348	41422			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		32320	G=8622	8622	G	A						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
Q17H	g.A51T	p.Q17H			25443	ORF3a	ORF3a	MISSENSE	41336	41348	41422						40804	T=531	531	T	A						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
Q27X	g.C79T	p.Q27X			27972	ORF8	ORF8	NONSENSE	40360	41422	41422						2	T=40358	40358	T	C						False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=True, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
Q289H	g.G867T	p.Q289H			29140	N	N	MISSENSE	64	64	41422						62	T=2	2	T	G						False	Q.4	Q.4=False	de_escalated		18-Dec-2020	
Q389H	g.G1167T	p.Q389H			29440	N	N	MISSENSE	9	9	41422						8	T=1	1	T	G						False	Q.3	Q.3=False	de_escalated		18-Dec-2020	
Q3966R	g.A11897G	p.Q3966R			12162	ORF1ab	ORF1a	MISSENSE	41385	41412	41422			nsp8	produced by both pp1a and pp1ab		39746	G=1639	1639	G	A						False	B.1.1.7, Q.4	Q.4=True, B.1.1.7=False	de_escalated		18-Dec-2020	
Q5267R	g.A15800G	p.Q5267R			16064	ORF1ab	ORF1b	MISSENSE	41293	41348	41422			RNA-dependent RNA polymerase	nsp12, NiRAN and RdRp, produced by pp1ab only		40991	G=302	302	G	A						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
Q62X	g.C184T	p.Q62X			27577	ORF7a	ORF7a	NONSENSE	40531	41349	41422						36715	T=3816	3816	T	C						False	Q.1, B.1.1.7	B.1.1.7=False, Q.1=True	de_escalated		18-Dec-2020	
R209_A211del	g.625_633delAGAATGGCT	p.R209_A211del			28894	N	N		41291	41348	41422						40837	TG=347	347	TG	TGCTAGAATGG						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
R2336K	g.G7007A	p.R2336K			7272	ORF1ab	ORF1a	MISSENSE	41149	41348	41422			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		40523	A=626	626	A	G						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
R24C	g.C70T	p.R24C			335	ORF1ab	ORF1a	MISSENSE	64	64	41422			leader protein	nsp1, produced by both pp1a and pp1ab		61	T=3	3	T	C						False	Q.4	Q.4=False	de_escalated		18-Dec-2020	
R3574K	g.G10721A	p.R3574K			10986	ORF1ab	ORF1a	MISSENSE	41025	41348	41422	caution	single_src,highly_ambiguous	nsp6	nsp6_TM, putative transmembrane domain, produced by both pp1a and pp1ab		40605	A=420	420	A	G						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
R4150R	g.A12450G	p.R4150R			12715	ORF1ab	ORF1a	SILENT	1	1	41422			nsp9	ssRNA-binding protein, produced by both pp1a and pp1ab		0	G=1	1	G	A						False	Q.1	Q.1=True	de_escalated		18-Dec-2020	
R52I	g.G155T	p.R52I			28048	ORF8	ORF8	MISSENSE	40358	41422	41422						2	T=40356	40356	T	G						False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=True, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
R545R	g.C1633A	p.R545R			1898	ORF1ab	ORF1a	SILENT	64	64	41422			nsp2	produced by both pp1a and pp1ab		63	A=1	1	A	C						False	Q.4	Q.4=False	de_escalated		18-Dec-2020	
R5716C	g.C17146T	p.R5716C			17410	ORF1ab	ORF1b	MISSENSE	41346	41348	41422			helicase	nsp13_ZBD, nsp13_TB, and nsp_HEL1core, zinc-binding domain (ZD), NTPase/helicase domain (HEL), RNA 5'-triphosphatase, produced by pp1ab only		40448	T=898	898	T	C						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
RG203KR	g.AGTAGGG604_610TCTAAAC	p.RG203KR			28877	N	N		41265	41348	41422						0	TCTAAAC=1017	1017	TCTAAAC	AGTAGGG						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
RG203KR	g.GGG608_610AAC	p.RG203KR			28877	N	N		41265	41348	41422						0	AGTAAAC=40237	40237	AGTAAAC	AGTAGGG						False	B.1.1.7	B.1.1.7=True	de_escalated		18-Dec-2020	
RG203KR	g.GGG608_610AAC	p.RG203KR			28881	N	N		74	74	41422						0	AAC=74	74	AAC	GGG						False	Q.1, Q.3, Q.4	Q.3=True, Q.4=True, Q.1=True	de_escalated		18-Dec-2020	
S1587L	g.C4760T	p.S1587L			5025	ORF1ab	ORF1a	MISSENSE	40935	41348	41422			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		40709	T=226	226	T	C						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
S194L	g.C581T	p.S194L			28854	N	N	MISSENSE	41305	41348	41422						39947	T=1358	1358	T	C	homoplasy	Barona-Gomez et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.05.18.21256128v1		Mutation with a population frequency of 30% in a Mexican dataset, primarily of lineage 20B, but also present in a substantial number of 20A lineage sequences, suggesting convergent evolution.	False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
S194L	g.C581T	p.S194L			28854	N	N	MISSENSE	41305	41348	41422						39947	T=1358	1358	T	C	outcome hazard ratio	Joshi et al. (2021)	https://doi.org/10.3389/fgene.2021.586569		In March 2021 this variant had an allele frequency of 47.62 and 7.25% in deceased patients, compared to 35.16 and 3.20% of the same variant in recovered patients, from the Gujarat and global datasets.	False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
S194L	g.C581T	p.S194L			28854	N	N	MISSENSE	41305	41348	41422						39947	T=1358	1358	T	C	symptom prevalence	Barona-Gomez et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.05.18.21256128v1		Mutation in the Nucleocapsid region showing a significant higher (ANOVA: F 	False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
S216S	g.C648T	p.S216S			913	ORF1ab	ORF1a	SILENT	40185	41422	41422			nsp2	produced by both pp1a and pp1ab		3	T=40182	40182	T	C						False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=True, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
S235F	g.C704T	p.S235F			28977	N	N	MISSENSE	41273	41422	41422						1	TTGT=287, T=74	287,74	TTGT,T	CTGG	variant linear antibody epitope effects	Haynes et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.01.06.20248960v1		Substantially increases epitope and antigen scores in 2 of 579 individuals (should increase immune response). In the B1.1.7 lineage this is largely counteracted by the D3L mutation, which decreases PIWAS signal significantly in 1.5% of COVID patients, for a net neutral effect at the population level.	False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=True, B.1.1.7=False, Q.1=True	de_escalated		18-Dec-2020	
S272G	g.A814G	p.S272G			26206	ORF3a	ORF3a	MISSENSE	64	64	41422						51	G=13	13	G	A						False	Q.4	Q.4=False	de_escalated		18-Dec-2020	
S2797F	g.C8390T	p.S2797F			8655	ORF1ab	ORF1a	MISSENSE	41104	41348	41422			nsp4	nsp4B_TM, contains transmembrane domain 2 (TM2), produced by both pp1a and pp1ab		40168	T=936	936	T	C						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
S3088S	g.A9264G	p.S3088S			9529	ORF1ab	ORF1a	SILENT	9	9	41422			nsp4	nsp4B_TM, contains transmembrane domain 2 (TM2), produced by both pp1a and pp1ab		1	G=8	8	G	A						False	Q.3	Q.3=True	de_escalated		18-Dec-2020	
S3570G	g.A10708G	p.S3570G			10973	ORF1ab	ORF1a	MISSENSE	41024	41348	41422			nsp6	nsp6_TM, putative transmembrane domain, produced by both pp1a and pp1ab		40561	G=463	463	G	A						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
S37P	g.T109C	p.S37P			28382	N	N	MISSENSE	41202	41348	41422						40701	C=501	501	C	T						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
S5424G	g.A16270G	p.S5424G			16534	ORF1ab	ORF1b	MISSENSE	41245	41348	41422			helicase	nsp13_ZBD, nsp13_TB, and nsp_HEL1core, zinc-binding domain (ZD), NTPase/helicase domain (HEL), RNA 5'-triphosphatase, produced by pp1ab only		40237	G=1008	1008	G	A						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
S549S	g.C1647T	p.S549S			1912	ORF1ab	ORF1a	SILENT	41327	41348	41422			nsp2	produced by both pp1a and pp1ab		41096	T=230	230	T	C						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
S60S	g.C180T	p.S60S			25572	ORF3a	ORF3a	SILENT	41345	41348	41422						41131	T=211	211	T	C						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
S6740F	g.C20219T	p.S6740F			20483	ORF1ab	ORF1b	MISSENSE	41174	41348	41422			endoRNAse	nsp15-A1 and nsp15B-NendoU, produced by pp1ab only		40308	T=866	866	T	C						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
S67F	g.C200T	p.S67F			28093	ORF8	ORF8	MISSENSE	40274	41357	41422						39587	T=687	687	T	C						False	B.1.1.7, Q.3	Q.3=True, B.1.1.7=False	de_escalated		18-Dec-2020	
S6800I	g.G20399T	p.S6800I			20663	ORF1ab	ORF1b	MISSENSE	41297	41348	41422			2'-O-ribose methyltransferase	nsp16_OMT, 2'-o-MT, produced by pp1ab only		40920	T=377	377	T	G						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
S982A	g.T2944G	p.S982A			24506	S	S	MISSENSE	40931	41422	41422						0	G=40931	40931	G	T	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.3x decrease in binding (KD) relative to D614G.	False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=True, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
S982A	g.T2944G	p.S982A			24506	S	S	MISSENSE	40931	41422	41422						0	G=40931	40931	G	T	ACE2 receptor binding affinity	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1		This mutation causes major decrease in binding affinity vs. wild type as measured by IC50 vs pseudotyped lentivirus.	False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=True, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
S982A	g.T2944G	p.S982A			24506	S	S	MISSENSE	40931	41422	41422						0	G=40931	40931	G	T	antibody epitope effects	Haynes et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.01.06.20248960v1		Not in a major wildtype epitope, mutant has no significant effect on PIWAS epitope score Found in B.1.1.7 lineage, but assumed to not pay a major role in antigenicity.	False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=True, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
S982A	g.T2944G	p.S982A			24506	S	S	MISSENSE	40931	41422	41422						0	G=40931	40931	G	T	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	1.06x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=True, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
S982A	g.T2944G	p.S982A			24506	S	S	MISSENSE	40931	41422	41422						0	G=40931	40931	G	T	convalescent plasma escape	Wang et al. (2021)	https://www.nature.com/articles/s41586-021-03398-2		The neutralizing activity of 6/20 convalescent sera was significantly lower against this single variant pseudotyped virus model, showing similar patterns to the pseudotyped virus model of B.1.1.7.	False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=True, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
S982A	g.T2944G	p.S982A			24506	S	S	MISSENSE	40931	41422	41422						0	G=40931	40931	G	T	environmental condition stability	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1		Relative to D614G, this mutation demonstrated significant increase in infectivity (i.e. heat stability) after incubation at 50C after 30 minutes or 1 hour	False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=True, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
S982A	g.T2944G	p.S982A			24506	S	S	MISSENSE	40931	41422	41422						0	G=40931	40931	G	T	trafficking	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1		Lentiviral pseudotyped with this individual mutation from B.1.1.7 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing major (70%) increase in infection rate amongst the cells, hence this individual variant  is likely to significantly contribute to cell entry fitness. 	False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=True, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
S982A	g.T2944G	p.S982A			24506	S	S	MISSENSE	40931	41422	41422						0	G=40931	40931	G	T	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	2x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.12x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=True, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
S98F	g.C293T	p.S98F			21855	S	S	MISSENSE	41312	41348	41422						40170	T=1142	1142	T	C						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
SG235FV	g.CTGG704_707TTGT	p.SG235FV			28977	N	N		41199	41348	41422						1	TTGG=40911	40911	TTGG	CTGG						False	B.1.1.7	B.1.1.7=True	de_escalated		18-Dec-2020	
T1001I	g.C3002T	p.T1001I			3267	ORF1ab	ORF1a	MISSENSE	41328	41422	41422			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		1	T=41327	41327	T	C						False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=True, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
T10I	g.C29T	p.T10I			27230	ORF6	ORF6	MISSENSE	41297	41348	41422						41059	T=238	238	T	C						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
T120I	g.C359T	p.T120I			27752	ORF7a	ORF7a	MISSENSE	40722	41348	41422						40005	T=717	717	T	C						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
T14I	g.C41T	p.T14I			25433	ORF3a	ORF3a	MISSENSE	41331	41348	41422						41054	T=277	277	T	C						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
T151I	g.C452T	p.T151I			25844	ORF3a	ORF3a	MISSENSE	41311	41349	41422						37184	T=4105	4105	T	C						False	Q.1, B.1.1.7	B.1.1.7=False, Q.1=True	de_escalated		18-Dec-2020	
T1567A	g.A4699G	p.T1567A			4964	ORF1ab	ORF1a	MISSENSE	64	64	41422			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		0	G=64	64	G	A						False	Q.4	Q.4=True	de_escalated		18-Dec-2020	
T1597I	g.C4790T	p.T1597I			5055	ORF1ab	ORF1a	MISSENSE	40945	41348	41422			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		40686	T=259	259	T	C						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
T1682I	g.C5045T	p.T1682I			5310	ORF1ab	ORF1a	MISSENSE	41316	41348	41422			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		38719	T=2597	2597	T	C						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
T175I	g.C524T	p.T175I			25916	ORF3a	ORF3a	MISSENSE	41296	41348	41422						40995	T=301	301	T	C						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
T1760I	g.C5279T	p.T1760I			5544	ORF1ab	ORF1a	MISSENSE	64	64	41422			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		11	T=53	53	T	C						False	Q.4	Q.4=True	de_escalated		18-Dec-2020	
T2069I	g.C6206T	p.T2069I			6471	ORF1ab	ORF1a	MISSENSE	64	64	41422			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		63	T=1	1	T	C						False	Q.4	Q.4=False	de_escalated		18-Dec-2020	
T2183I	g.C6548T	p.T2183I			6813	ORF1ab	ORF1a	MISSENSE	41321	41348	41422			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		41045	T=276	276	T	C						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
T223I	g.C668T	p.T223I			26060	ORF3a	ORF3a	MISSENSE	64	64	41422						63	T=1	1	T	C						False	Q.4	Q.4=False	de_escalated		18-Dec-2020	
T2274I	g.C6821T	p.T2274I			7086	ORF1ab	ORF1a	MISSENSE	41328	41348	41422			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		40189	T=1139	1139	T	C						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
T22I	g.C65T	p.T22I			21627	S	S	MISSENSE	1	1	41422						0	T=1	1	T	C						False	Q.1	Q.1=True	de_escalated		18-Dec-2020	
T2846I	g.C8537T	p.T2846I			8802	ORF1ab	ORF1a	MISSENSE	41218	41348	41422			nsp4	nsp4B_TM, contains transmembrane domain 2 (TM2), produced by both pp1a and pp1ab		40841	T=377	377	T	C						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
T2872M	g.C8615T	p.T2872M			8880	ORF1ab	ORF1a	MISSENSE	41228	41348	41422			nsp4	nsp4B_TM, contains transmembrane domain 2 (TM2), produced by both pp1a and pp1ab		40919	T=309	309	T	C						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
T3258T	g.C9774T	p.T3258T			10039	ORF1ab	ORF1a	SILENT	41309	41348	41422			nsp4	nsp4B_TM, contains transmembrane domain 2 (TM2), produced by both pp1a and pp1ab		39884	T=1425	1425	T	C						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
T333M	g.C998T	p.T333M			1263	ORF1ab	ORF1a	MISSENSE	41329	41348	41422			nsp2	produced by both pp1a and pp1ab		39451	T=1878	1878	T	C						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
T379I	g.C1136T	p.T379I			29409	N	N	MISSENSE	63	64	41422						60	T=3	3	T	C	homoplasy	Borges et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.05.19.444774v1		In experimental models of SARS-CoV-2 mutational evolution (without immune pressure), this mutation appears convergent. 	False	Q.4	Q.4=False	de_escalated		18-Dec-2020	
T3904T	g.T11712C	p.T3904T			11977	ORF1ab	ORF1a	SILENT	41321	41348	41422			nsp7	produced by both pp1a and pp1ab		40912	C=409	409	C	T						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
T4129I	g.C12386T	p.T4129I			12651	ORF1ab	ORF1a	MISSENSE	41274	41348	41422			nsp8	produced by both pp1a and pp1ab		40978	T=296	296	T	C						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
T4164I	g.C12491T	p.T4164I			12756	ORF1ab	ORF1a	MISSENSE	1	1	41422			nsp9	ssRNA-binding protein, produced by both pp1a and pp1ab		0	T=1	1	T	C						False	Q.1	Q.1=True	de_escalated		18-Dec-2020	
T417T	g.T1251C	p.T417T			29524	N	N	SILENT	41216	41349	41422						37323	C=3893	3893	C	T						False	Q.1, B.1.1.7	B.1.1.7=False, Q.1=True	de_escalated		18-Dec-2020	
T4786M	g.C14357T	p.T4786M			14621	ORF1ab	ORF1b	MISSENSE	41344	41348	41422			RNA-dependent RNA polymerase	nsp12, NiRAN and RdRp, produced by pp1ab only		41079	T=265	265	T	C						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
T4957T	g.T14871C	p.T4957T			15135	ORF1ab	ORF1b	SILENT	41342	41348	41422			RNA-dependent RNA polymerase	nsp12, NiRAN and RdRp, produced by pp1ab only		41094	C=248	248	C	T						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
T4983I	g.C14948T	p.T4983I			15212	ORF1ab	ORF1b	MISSENSE	41343	41348	41422			RNA-dependent RNA polymerase	nsp12, NiRAN and RdRp, produced by pp1ab only		41136	T=207	207	T	C						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
T5304T	g.T15912C	p.T5304T			16173	ORF1ab	ORF1b	SILENT	41263	41348	41422			RNA-dependent RNA polymerase	nsp12, NiRAN and RdRp, produced by pp1ab only		12	CACC=40211	40211	CACC	CACT						False	B.1.1.7	B.1.1.7=True	de_escalated		18-Dec-2020	
T5304T	g.T15912C	p.T5304T			16176	ORF1ab	ORF1b	SILENT	74	74	41422			RNA-dependent RNA polymerase	nsp12, NiRAN and RdRp, produced by pp1ab only		0	C=74	74	C	T						False	Q.1, Q.3, Q.4	Q.3=True, Q.4=True, Q.1=True	de_escalated		18-Dec-2020	
T592I	g.C1775T	p.T592I			2040	ORF1ab	ORF1a	MISSENSE	41331	41348	41422			nsp2	produced by both pp1a and pp1ab		40952	T=378	378	T	C						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
T6949I	g.C20846T	p.T6949I			21110	ORF1ab	ORF1b	MISSENSE	64	64	41422			2'-O-ribose methyltransferase	nsp16_OMT, 2'-o-MT, produced by pp1ab only		61	T=3	3	T	C						False	Q.4	Q.4=False	de_escalated		18-Dec-2020	
T6989T	g.A20967G	p.T6989T			21231	ORF1ab	ORF1b	SILENT	40242	41348	41422			2'-O-ribose methyltransferase	nsp16_OMT, 2'-o-MT, produced by pp1ab only		40029	G=213	213	G	A						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
T708I	g.C2123T	p.T708I			2388	ORF1ab	ORF1a	MISSENSE	64	64	41422			nsp2	produced by both pp1a and pp1ab		60	T=4	4	T	C						False	Q.4	Q.4=False	de_escalated		18-Dec-2020	
T716I	g.C2147T	p.T716I			23709	S	S	MISSENSE	40941	41422	41422						0	T=40941	40941	T	C	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.12x decrease in binding (KD) relative to D614G.	False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=True, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
T716I	g.C2147T	p.T716I			23709	S	S	MISSENSE	40941	41422	41422						0	T=40941	40941	T	C	anthropozoonotic events	McAloose et al. (2020)	https://dx.doi.org/10.1128/mBio.02220-20		Observed first in a single tiger (cohort of 5), potential adaptation.	False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=True, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
T716I	g.C2147T	p.T716I			23709	S	S	MISSENSE	40941	41422	41422						0	T=40941	40941	T	C	antibody epitope effects	Haynes et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.01.06.20248960v1		Not in a major wildtype epitope, mutant increases PIWAS epitope score from 0.69% to 2.3% Found in B.1.1.7 lineage, but assumed to not pay a major role in antigenicity.	False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=True, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
T716I	g.C2147T	p.T716I			23709	S	S	MISSENSE	40941	41422	41422						0	T=40941	40941	T	C	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	1.58x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=True, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
T716I	g.C2147T	p.T716I			23709	S	S	MISSENSE	40941	41422	41422						0	T=40941	40941	T	C	trafficking	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1		Lentiviral pseudotyped with this individual mutation from B.1.1.7 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing major decrease in infection rate amongst the cells, hence this individual variant  is unlikely to contribute to cell entry fitness. T716I was expressed at significantly lower level, accounting for the decreased infectivity of this spike protein. This property may be specific to spike protein biosynthesis in 293T cells and is not likely to reflect the situation in vivo given the reported increase in infectivity of the B.1.1.7 virus.	False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=True, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
T716I	g.C2147T	p.T716I			23709	S	S	MISSENSE	40941	41422	41422						0	T=40941	40941	T	C	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	1.02x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.47x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=True, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
T760I	g.C2279T	p.T760I			2544	ORF1ab	ORF1a	MISSENSE	41346	41348	41422			nsp2	produced by both pp1a and pp1ab		39782	T=1564	1564	T	C						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
T814I	g.C2441T	p.T814I			2706	ORF1ab	ORF1a	MISSENSE	64	64	41422			nsp2	produced by both pp1a and pp1ab		57	T=7	7	T	C						False	Q.4	Q.4=False	de_escalated		18-Dec-2020	
T821I	g.C2462T	p.T821I			2727	ORF1ab	ORF1a	MISSENSE	41301	41348	41422			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		40711	T=590	590	T	C						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
V1025V	g.G3075T	p.V1025V			3340	ORF1ab	ORF1a	SILENT	41265	41348	41422			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		40384	T=881	881	T	G						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
V1118V	g.C3354T	p.V1118V			3619	ORF1ab	ORF1a	SILENT	41261	41348	41422			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		40941	T=320	320	T	C						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
V1583F	g.G4747T	p.V1583F			5012	ORF1ab	ORF1a	MISSENSE	27	64	41422			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		26	T=1	1	T	G						False	Q.4	Q.4=False	de_escalated		18-Dec-2020	
V2665V	g.T7995C	p.V2665V			8260	ORF1ab	ORF1a	SILENT	41326	41349	41422			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		38011	C=3315	3315	C	T						False	Q.1, B.1.1.7	B.1.1.7=False, Q.1=True	de_escalated		18-Dec-2020	
V3021V	g.A9063G	p.V3021V			9328	ORF1ab	ORF1a	SILENT	63	64	41422			nsp4	nsp4B_TM, contains transmembrane domain 2 (TM2), produced by both pp1a and pp1ab		62	G=1	1	G	A						False	Q.4	Q.4=False	de_escalated		18-Dec-2020	
V3377V	g.G10131T	p.V3377V			10396	ORF1ab	ORF1a	SILENT	9	9	41422			3C-like proteinase	nsp5A_3CLpro and nsp5B_3CLpro, main proteinase (Mpro), mediates cleavages downstream of nsp4. 3D structure of the SARSr-CoV homolog has been determined (Yang et al., 2003), produced by both pp1a and pp1ab		0	T=9	9	T	G						False	Q.3	Q.3=True	de_escalated		18-Dec-2020	
V3660V	g.G10980A	p.V3660V			11245	ORF1ab	ORF1a	SILENT	41335	41348	41422			nsp6	nsp6_TM, putative transmembrane domain, produced by both pp1a and pp1ab		41014	A=321	321	A	G						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
V3748I	g.G11242A	p.V3748I			11507	ORF1ab	ORF1a	MISSENSE	41326	41348	41422			nsp6	nsp6_TM, putative transmembrane domain, produced by both pp1a and pp1ab		40640	A=686	686	A	G						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
V378G	g.T1133G	p.V378G			1398	ORF1ab	ORF1a	MISSENSE	64	64	41422			nsp2	produced by both pp1a and pp1ab		63	G=1	1	G	T						False	Q.4	Q.4=False	de_escalated		18-Dec-2020	
V382V	g.G1146A	p.V382V			22708	S	S	SILENT	41273	41348	41422						40882	A=382	382	A	G						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
V49L	g.G145T	p.V49L			26389	E	E	MISSENSE	41299	41348	41422						41005	T=294	294	T	G						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
V5954V	g.T17862A	p.V5954V			18126	ORF1ab	ORF1b	SILENT	41300	41348	41422			3'-to-5' exonuclease	nsp14A2_ExoN and nsp14B_NMT, produced by pp1ab only		41008	A=291	291	A	T						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
V62L	g.G184T	p.V62L			28077	ORF8	ORF8	MISSENSE	40282	41348	41422						40032	T=226	226	T	G						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
V6391V	g.A19173G	p.V6391V			19437	ORF1ab	ORF1b	SILENT	61	64	41422			3'-to-5' exonuclease	nsp14A2_ExoN and nsp14B_NMT, produced by pp1ab only		60	G=1	1	G	A						False	Q.4	Q.4=False	de_escalated		18-Dec-2020	
V6916V	g.A20748C	p.V6916V			21012	ORF1ab	ORF1b	SILENT	41091	41348	41422			2'-O-ribose methyltransferase	nsp16_OMT, 2'-o-MT, produced by pp1ab only		40092	C=999	999	C	A						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
V6937V	g.T20811A	p.V6937V			21075	ORF1ab	ORF1b	SILENT	9	9	41422			2'-O-ribose methyltransferase	nsp16_OMT, 2'-o-MT, produced by pp1ab only		8	A=1	1	A	T						False	Q.3	Q.3=False	de_escalated		18-Dec-2020	
V705V	g.T2115C	p.V705V			23677	S	S	SILENT	40829	41348	41422						40529	C=300	300	C	T						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
V70L	g.G208C	p.V70L			26730	M	M	MISSENSE	9	9	41422						0	C=9	9	C	G						False	Q.3	Q.3=True	de_escalated		18-Dec-2020	
W131C	g.G393T	p.W131C			25785	ORF3a	ORF3a	MISSENSE	41307	41348	41422						36652	T=4653	4653	T	G						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
W45R	g.T133C	p.W45R			25525	ORF3a	ORF3a	MISSENSE	41343	41348	41422						41082	C=261	261	C	T						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
Y145del	g.432_434delTTA	p.Y145del			21987	S	S		39550	41348	41422						856	GTGTTTAC=38422	38422	GTGTTTAC	GTGTTTATTAC	convalescent plasma escape	Li et al. (2020)	https://www.sciencedirect.com/science/article/abs/pii/S0092867420308771		Resistant to a pool of 10 convalescent sera (but less than 4x, a typical threshold for definition of escape)	False	B.1.1.7	B.1.1.7=True	de_escalated		18-Dec-2020	
Y145del	g.432_434delTTA	p.Y145del			21987	S	S		39550	41348	41422						856	GTGTTTAC=38422	38422	GTGTTTAC	GTGTTTATTAC	convalescent plasma escape	McCarthy et al. (2021)	https://doi.org/10.1126/science.abf6950		Virus evolution data in 9 immunocomprised patients with long active COVID-19 infections was gathered, showing sequence deletion hotspots. This variant was present in 1 patient.	False	B.1.1.7	B.1.1.7=True	de_escalated		18-Dec-2020	
Y145del	g.432_434delTTA	p.Y145del			21990	S	S		61	74	41422						0	TTTAC=61	61	TTTAC	TTTATTAC	convalescent plasma escape	Li et al. (2020)	https://www.sciencedirect.com/science/article/abs/pii/S0092867420308771		Resistant to a pool of 10 convalescent sera (but less than 4x, a typical threshold for definition of escape)	False	Q.1, Q.3, Q.4	Q.3=True, Q.4=True, Q.1=True	de_escalated		18-Dec-2020	
Y145del	g.432_434delTTA	p.Y145del			21990	S	S		61	74	41422						0	TTTAC=61	61	TTTAC	TTTATTAC	convalescent plasma escape	McCarthy et al. (2021)	https://doi.org/10.1126/science.abf6950		Virus evolution data in 9 immunocomprised patients with long active COVID-19 infections was gathered, showing sequence deletion hotspots. This variant was present in 1 patient.	False	Q.1, Q.3, Q.4	Q.3=True, Q.4=True, Q.1=True	de_escalated		18-Dec-2020	
Y2489Y	g.C7467T	p.Y2489Y			7732	ORF1ab	ORF1a	SILENT	41276	41348	41422			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		40129	T=1147	1147	T	C						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
Y298Y	g.C894T	p.Y298Y			29167	N	N	SILENT	41251	41348	41422						40846	T=405	405	T	C						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
Y333Y	g.C999T	p.Y333Y			29272	N	N	SILENT	41253	41348	41422						41008	T=245	245	T	C						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
Y508Y	g.C1524T	p.Y508Y			23086	S	S	SILENT	41082	41348	41422						39811	T=1271	1271	T	C						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
Y5541Y	g.C16623T	p.Y5541Y			16887	ORF1ab	ORF1b	SILENT	41337	41348	41422	mask	highly_homoplasic	helicase	nsp13_ZBD, nsp13_TB, and nsp_HEL1core, zinc-binding domain (ZD), NTPase/helicase domain (HEL), RNA 5'-triphosphatase, produced by pp1ab only		40885	T=452	452	T	C						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
Y6160Y	g.C18480T	p.Y6160Y			18744	ORF1ab	ORF1b	SILENT	64	64	41422			3'-to-5' exonuclease	nsp14A2_ExoN and nsp14B_NMT, produced by pp1ab only		63	T=1	1	T	C						False	Q.4	Q.4=False	de_escalated		18-Dec-2020	
Y6345Y	g.T19035C	p.Y6345Y			19299	ORF1ab	ORF1b	SILENT	39380	41348	41422	mask	homoplasic,ambiguous,narrow_src	3'-to-5' exonuclease	nsp14A2_ExoN and nsp14B_NMT, produced by pp1ab only		39147	C=233	233	C	T						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
Y73C	g.A218G	p.Y73C			28111	ORF8	ORF8	MISSENSE	40360	41422	41422						3	G=40356	40356	G	A						False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=True, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
Y97Y	g.C291T	p.Y97Y			27684	ORF7a	ORF7a	SILENT	40636	41348	41422						40380	T=256	256	T	C						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
g.A29700G	g.A29700G				29700	intergenic	intergenic		41050	41348	41422						39679	G=1371	1371	G	A						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
g.A29806G	g.A29806G				29806	intergenic	intergenic		15838	41348	41422	mask	seq_end				15629	G=209	209	G	A						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
g.AGGCCACGCGGAGTACGATCGAGTGT29735AGGCCACGCGTAGTACGATCGAGTGT	g.AGGCCACGCGGAGTACGATCGAGTGT29735AGGCCACGCGTAGTACGATCGAGTGT				29735	intergenic	intergenic		63	64	41422						61	AGGCCACGCGTAGTACGATCGAGTGT=1	1	AGGCCACGCGTAGTACGATCGAGTGT	AGGCCACGCGGAGTACGATCGAGTGT						False	Q.4	Q.4=False	de_escalated		18-Dec-2020	
g.AGGCCACGCGGAGTACGATCGAGTGT29735AT	g.AGGCCACGCGGAGTACGATCGAGTGT29735AT				29735	intergenic	intergenic		63	64	41422						61	AT=1	1	AT	AGGCCACGCGGAGTACGATCGAGTGT						False	Q.4	Q.4=False	de_escalated		18-Dec-2020	
g.C-104T	g.C-104T				162	ORF1ab	intergenic		41305	41348	41422						40177	T=1128	1128	T	C						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
g.C-119T	g.C-119T				147	ORF1ab	intergenic		41302	41348	41422						40593	T=709	709	T	C						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
g.C-25T	g.C-25T				241	ORF1ab	intergenic		41375	41422	41422						3	T=41372	41372	T	C						False	Q.1, B.1.1.7, Q.3, Q.4	Q.3=True, Q.4=True, B.1.1.7=True, Q.1=True	de_escalated		18-Dec-2020	
g.C-59T	g.C-59T				207	ORF1ab	intergenic		41295	41348	41422						40980	T=312	312	T	C						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
g.C29743T	g.C29743T				29743	intergenic	intergenic		40833	41348	41422						40517	T=316	316	T	C						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
g.G-56T	g.G-56T				210	ORF1ab	intergenic		41293	41348	41422						40927	T=366	366	T	G						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
g.G29734T	g.G29734T				29734	intergenic	intergenic		40906	41348	41422						39708	T=1194	1194	T	G						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
g.G29764A	g.G29764A				29764	intergenic	intergenic		39244	41348	41422						36039	A=3202	3202	A	G						False	B.1.1.7	B.1.1.7=False	de_escalated		18-Dec-2020	
